# STIC Search Report
## Biotech-Chem Library

STIC Database Tracking Number: 164479

| | |
|---|---|
| **TO: Rei-Tsang Shiao**<br>**Location: 5a10 / 5c18**<br>**Art Unit: 1626**<br>**Thursday, September 22, 2005**<br><br>**Case Serial Number: 10/693327** | **From: Noble Jarrell**<br>**Location: Biotech-Chem Library**<br>**Rem 1B71**<br>**Phone: 272-2556**<br><br>**Noble.jarrell@uspto.gov** |

## Search Notes

```
=> d his full

     (FILE 'HOME' ENTERED AT 08:52:27 ON 22 SEP 2005)

     FILE 'HCAPLUS' ENTERED AT 08:52:42 ON 22 SEP 2005
L1            1 SEA ABB=ON  PLU=ON  US2004162278/PN OR (US2003-693327# OR
                GB2002-24919# OR US2002-428632#)/AP,PRN

     FILE 'REGISTRY' ENTERED AT 08:54:54 ON 22 SEP 2005

     FILE 'HCAPLUS' ENTERED AT 08:54:54 ON 22 SEP 2005
L2            TRA L1 1- RN :      221 TERMS

     FILE 'REGISTRY' ENTERED AT 08:54:54 ON 22 SEP 2005
L3          221 SEA ABB=ON  PLU=ON  L2

     FILE 'WPIX' ENTERED AT 08:55:04 ON 22 SEP 2005
L4            1 SEA ABB=ON  PLU=ON  US2004162278/PN OR (US2003-693327# OR
                GB2002-24919# OR US2002-428632#)/AP,PRN


     FILE HOME

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 22 Sep 2005  VOL 143 ISS 13
     FILE LAST UPDATED: 21 Sep 2005  (20050921/ED)

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

      This file contains CAS Registry Numbers for easy and accurate
      substance identification.

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   21 SEP 2005  HIGHEST RN 863636-50-4
     DICTIONARY FILE UPDATES:  21 SEP 2005  HIGHEST RN 863636-50-4

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

FILE WPIX
FILE LAST UPDATED: 20 SEP 2005 <20050920/UP>
MOST RECENT DERWENT UPDATE: 200560 <200560/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT: http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://thomsonderwent.com/coverage/latestupdates/ <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER GUIDES, PLEASE VISIT: http://thomsonderwent.com/support/userguides/ <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX FIRST VIEW - FILE WPIFV. FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501. PLEASE CHECK: http://thomsonderwent.com/support/dwpiref/reftools/classification/code-rev FOR DETAILS. <<<

=> b hcap
FILE 'HCAPLUS' ENTERED AT 08:55:34 ON 22 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 22 Sep 2005 VOL 143 ISS 13
FILE LAST UPDATED: 21 Sep 2005 (20050921/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all l1 tot

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:370921 HCAPLUS
DN 140:391283
ED Entered STN: 07 May 2004
TI Preparation of triazoles as vasopressin receptor V1a antagonists for

treating of dysmenorrhea
IN Armour, Robert Duncan; Baxter, Andrew Douglas; Bryans, Justin Stephen; Dack, Kevin Neil; Johnson, Patrick Stephen; Lewthwaite, Russell Andrew; Newman, Julie; Rawson, David James; Ryckmans, Thomas
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D401-04
ICS C07D401-06; C07D401-14; C07D413-04; C07D413-06; C07D413-14; A61K031-4196; A61P009-00; A61P007-00; A61P013-00; A61P025-00; C07D403-12; C07D401-12; C07D405-14
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|---|---|---|---|---|---|---|
| PI | WO 2004037809 | A1 | 20040506 | WO 2003-IB4587 | 20031014 | <-- |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | CA 2502932 | AA | 20040506 | CA 2003-2502932 | 20031014 | <-- |
| | EP 1558598 | A1 | 20050803 | EP 2003-748487 | 20031014 | <-- |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | | |
| | US 2004162278 | A1 | 20040819 | US 2003-693327 | 20031024 | <-- |
| PRAI | GB 2002-24919 | A | 20021025 | <-- | | |
| | US 2002-428632P | P | 20021122 | <-- | | |
| | WO 2003-IB4587 | W | 20031014 | | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|
| WO 2004037809 | ICM | C07D401-04 |
| | ICS | C07D401-06; C07D401-14; C07D413-04; C07D413-06; C07D413-14; A61K031-4196; A61P009-00; A61P007-00; A61P013-00; A61P025-00; C07D403-12; C07D401-12; C07D405-14 |
| WO 2004037809 | ECLA | C07D401/04+249B+211; C07D401/06+249B+211; C07D401/12+249B+213; C07D401/14+249B+213+211; C07D401/14+249B+239B+211; C07D401/14+249B+241B+211; C07D401/14+249B+213+211+211; C07D401/14+249B+213+211+207; C07D401/14+249B+239B+211+211; C07D401/14+249B+249+213+211; C07D401/14+249B+213+213+211; C07D403/12+249B+239B; C07D405/14+307B+249B+213+211; C07D405/14+309+249B+213+211; C07D413/04+271+211; C07D413/06+271+211; C07D413/14+271+213+211; C07D413/14+271+213+211+211; C07D413/14+271+239B+211 <-- |
| CA 2502932 | ECLA | C07D401/04+249B+211; C07D401/06+249B+211; C07D401/12+249B+213; C07D401/14+249B+213+211; C07D401/14+249B+213+211+207; C07D401/14+249B+213+211+211; C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211; C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211; C07D401/14+249B+249+213+211; C07D403/12+249B+239B; C07D405/14+307B+249B+213+211; C07D405/14+309+249B+213+211; C07D413/04+271+211; |

C07D413/06+271+211; C07D413/14+271+213+211;
C07D413/14+271+213+211+211; C07D413/14+271+239B+211 <--
EP 1558598 ECLA C07D401/04+249B+211; C07D401/06+249B+211;
C07D401/12+249B+213; C07D401/14+249B+213+211;
C07D401/14+249B+213+211+207;
C07D401/14+249B+213+211+211;
C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211;
C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211;
C07D401/14+249B+249+213+211; C07D403/12+249B+239B;
C07D405/14+307B+249B+213+211;
C07D405/14+309+249B+213+211; C07D413/04+271+211;
C07D413/06+271+211; C07D413/14+271+213+211;
C07D413/14+271+213+211+211; C07D413/14+271+239B+211 <--
US 2004162278 NCL 514/210.200
ECLA C07D401/04+249B+211; C07D401/06+249B+211;
C07D401/12+249B+213; C07D401/14+249B+213+211;
C07D401/14+249B+213+211+207;
C07D401/14+249B+213+211+211;
C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211;
C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211;
C07D401/14+249B+249+213+211; C07D403/12+249B+239B;
C07D405/14+307B+249B+213+211;
C07D405/14+309+249B+213+211; C07D413/04+271+211;
C07D413/06+271+211; C07D413/14+271+213+211;
C07D413/14+271+213+211+211; C07D413/14+271+239B+211 <--
OS MARPAT 140:391283
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = cyclo/alkyl, (CH2)cW, (CH2)cZ(CH2)dW; W = alkyl, alkyloxy, CONH2 and derivs., NH2 and derivs., (un)substituted Ph, etc.; Z = O or S(O)g; g = 0-2; R2 = Ph optionally fused to a 5- or 6-membered aryl or heteroaryl; Y = (CHR3)a; R3 = independently H, alkyl, OH and derivs., etc.; X = (CH2)b; a, b = independently 0-1; c, d = 0-4; A = 4-, 5- or 6-membered saturated heterocyclyl, B = (un)substituted Ph, 4-, 5-, or 6-membered (un)saturated heterocyclyl; their pharmaceutically acceptable salts and solvates] were prepared as vasopressin receptor V1a antagonists for the treatment of dysmenorrhea. Thus, reacting oxadiazole II (preparation given) with (S)-1-phenylethylamine in the presence of anhydrous MgCl2 at 150° gave triazole III. I showed Ki values < 500 nM in a V1a filter binding assay.
ST triazole prepn V1a antagonist dysmenorrhea
IT Blood vessel, disease
(Raynaud's phenomenon, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Vasopressin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(V1a, antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Behavior
(aggressive; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Appetite
(anorexia nervosa, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Antiarteriosclerotics
(antiatherosclerotics; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Ischemia
(cardiac, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Nervous system, disease

(central; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Mental disorder
(cognitive, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Mental disorder
(depression, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Urogenital tract
(disease, infection, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Sexual behavior
(disorder, treatment of male and female; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Cognition
(disorder, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Uterus, disease
(endometriosis, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Heart, disease
Kidney, disease
(failure, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Reproductive tract, disease
(female, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Embryo, animal, disease
(fetus, intrauterine growth retardation, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Spinal cord, disease
(injury, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Heart, disease
(ischemia, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Diabetes mellitus
(non-insulin-dependent, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Mental disorder
(obsession-compulsion, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Contraceptives
Drug delivery systems
(oral; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Sexual behavior
(premature ejaculation, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Parturition
(premature, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Anti-Alzheimer's agents
Anti-ischemic agents
Antiasthmatics
Antidepressants
Antidiabetic agents
Antiemetics
Antiglaucoma agents
Antihypertensives
Antiobesity agents
Antitumor agents
Anxiolytics
Cardiovascular agents
Cognition enhancers
Diuretics

Human
Hypnotics and Sedatives
Thrombolytics
(preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Injury
(spinal cord, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Ischemia
(treatment of cerebrovascular; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Alzheimer's disease
Anxiety
Asthma
Atherosclerosis
Calculi, urinary
Cardiovascular system, disease
Cataract
Cirrhosis
Cushing's syndrome
Diabetes mellitus
Digestive tract, disease
Dysmenorrhea
Edema
Glaucoma (disease)
Heart, disease
Hypertension
Ischemia
Kidney
Kidney, disease
Lung, disease
Lung, neoplasm
Micturition
Motion sickness
Neoplasm
Nervous system agents
Obesity
Sleep disorders
Thrombosis
Vomiting
(treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Infection
(urogenital, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 685827-43-4P, 4-[4-Benzyl-5-[4-(methanesulfonyl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
685827-47-8P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3'-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(V1A receptor antagonist, V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 685827-36-5P, 4-[4-(3-Chlorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-69-4P, 4-[4-Benzyl-5-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(V1A receptor antagonist; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

IT 685827-26-3P, Benzyl 4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazine-1-carboxylate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(V1a receptor antagonist, intermediate; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 685826-99-7P, (S)-4-[5-Butyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-00-3P, 2-[4-(4-Benzyl-5-isobutyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-01-4P, (S)-4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-02-5P, 4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-03-6P, 2-[4-(4-Benzyl-5-isopropyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-04-7P, 2-[4-(4-Benzyl-5-cyclopropyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-05-8P, (S)-2-[4-[5-Methyl-4-(1-phenylpropyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-06-9P, 2-[4-(4-Benzyl-5-propyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-07-0P, 2-[4-[4-Benzyl-5-(2-chlorophenoxymethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-08-1P, 2-[4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-09-2P, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-10-5P, 2-[4-[4-Benzyl-5-(4-fluorophenoxymethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-11-6P, 2-[4-[5-Methyl-4-(3-methylbenzyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-12-7P, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-ylmethyl]piperidin-1-yl]pyrimidine 685827-13-8P, 2-[4-[4-(3-Fluorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-14-9P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-15-0P, 4-[4-Benzyl-5-[(benzyloxy)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-16-1P, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-17-2P, (R)-2-[3-Methyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-[1,2,4]triazol-4-yl]-2-phenylethanol 685827-18-3P, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]-4-methylpyrimidine 685827-19-4P, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-20-7P, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-1-phenylpiperidine 685827-21-8P, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrazine 685827-22-9P, 4-(4-Benzyl-5-[(piperidin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-23-0P, (S)-4-[4-(1-Phenylethyl)-5-[(piperidin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-24-1P, 4-[4-Benzyl-5-(4-methoxypiperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-25-2P, (S)-4-[5-(4-Methoxypiperidin-1-ylmethyl)-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-27-4P, 4-[4-Benzyl-5-[[2-(morpholin-4-yl)ethoxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-28-5P, 4-[4-Benzyl-5-((3R)-3-methoxypyrrolidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-29-6P 685827-30-9P 685827-31-0P 685827-32-1P 685827-33-2P 685827-34-3P 685827-35-4P 685827-37-6P, N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]acetamide 685827-38-7P, 2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethylamine 685827-39-8P, N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]ethylamine 685827-40-1P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)amine 685827-41-2P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)amine 685827-42-3P, 1-[4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazin-1-yl]ethanone 685827-44-5P, N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]methanesulfonamide 685827-45-6P,

[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)methylamine 685827-46-7P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)methylamine 685827-48-9P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-49-0P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carbonitrile 685827-50-3P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carboxylic acid amide 685827-51-4P, (S)-4-[[4-(1-Phenylethyl)-5-[4-(pyridin-2-yl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]methyl]morpholine trihydrochloride 685827-52-5P, (S)-4-[[4-(1-Phenylethyl)-5-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]-4H-[1,2,4]triazol-3-yl]methyl]morpholine trihydrochloride 685827-53-6P, 1-[[4-Benzyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]piperidin-3-ol 685827-54-7P, (R)-2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 685827-55-8P, (R)-4-[4-Benzyl-5-[[(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-56-9P, (S)-4-[4-Benzyl-5-[[(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-57-0P, [[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]methylamino]acetic acid tert-butyl ester 685827-58-1P, 4-[4-Benzyl-5-(tetrahydropyran-4-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-59-2P, 4-[4-Benzyl-5-(tetrahydrofuran-2-yl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-60-5P, 4-[4-Benzyl-5-(ethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-61-6P, 4-[4-Benzyl-5-(2-methoxyethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-62-7P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]acetic acid tert-butyl ester 685827-63-8P, N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]acetamide 685827-64-9P, 4-[4-Benzyl-5-[(methylsulfanyl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-65-0P, 4-(4-Benzyl-5-[(pyrazol-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-66-1P, 4-(4-Benzyl-5-[([1,2,3]triazol-2-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-67-2P, 4-(4-Benzyl-5-[1,2,3]triazol-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-68-3P, 4-[4-Benzyl-5-(pyridin-4-yloxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 7440-23-5, Sodium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyponatremia; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 474707-30-7P, (3R)-3-Methoxypyrrolidine hydrochloride 549532-08-3P, (3R)-3-Methoxypyrrolidine-1-carboxylic acid tert-butyl ester 550371-69-2P, (3S)-3-Methoxypyrrolidine-1-carboxylic acid tert-butyl ester 685827-70-7P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid 685827-71-8P, N'-Butyryl-1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685827-72-9P 685827-73-0P 685827-74-1P 685827-75-2P 685827-76-3P 685827-77-4P 685827-78-5P 685827-79-6P 685827-80-9P, N'-Pentanoyl-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685827-81-0P, N'-Acetyl-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685827-82-1P, N'-[2-(Morpholin-4-yl)acetyl]-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685827-83-2P, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide monohydrochloride 685827-84-3P,

N'-(3-Methylbutyryl)-1-(pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685827-86-5P, 2-[4-(5-Isobutyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine 685827-87-6P 685827-88-7P 685827-89-8P 685827-90-1P 685827-91-2P 685827-92-3P 685827-93-4P 685827-94-5P 685827-95-6P 685827-96-7P 685827-97-8P, 2-[4-(5-Methyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine 685827-98-9P, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester 685827-99-0P, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidine monohydrochloride 685828-00-6P, 4-[(5-Methyl-[1,3,4]oxadiazol-2-yl)methyl]piperidine monohydrochloride 685828-01-7P, 2-[4-[(5-Methyl-[1,3,4]oxadiazol-2-yl)methyl]piperidin-1-yl]pyrimidine 685828-02-8P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-03-9P, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685828-04-0P, N'-(2-Benzyloxyacetyl)-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-05-1P, 4-[5-[(Benzyloxy)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-06-2P, N'-(2-Chloroacetyl)-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-07-3P, N'-(2-Chloroacetyl)-1-(pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685828-08-4P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-09-5P, 2-[4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine 685828-10-8P, 4-[5-[(Piperidin-1-yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-11-9P 685828-12-0P 685828-13-1P, 4-[5-[[2-(Morpholin-4-yl)ethoxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-14-2P, 3-Oxo-3-[2-[(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-4-yl)carbonyl]hydrazino]propionic acid tert-butyl ester 685828-15-3P, [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-yl]acetic acid tert-butyl ester 685828-16-4P, (3S)-3-Methoxypyrrolidine hydrochloride 685828-17-5P 685828-18-6P 685828-19-7P 685828-20-0P 685828-21-1P 685828-22-2P 685828-23-3P 685828-24-4P 685828-25-5P, Ethyl-[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-ylmethyl]amine 685828-26-6P, [2-[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-ylmethoxy]ethyl]carbamic acid tert-butyl ester 685828-27-7P, [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-ylmethyl]carbamic acid tert-butyl ester 685828-28-8P 685828-29-9P 685828-30-2P 685828-31-3P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]carbamic acid tert-butyl ester 685828-32-4P 685828-33-5P 685828-34-6P 685828-35-7P, [2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethyl]carbamic acid tert-butyl ester 685828-36-8P 685828-37-9P, 4-(4-Benzyl-5-[(piperazin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-38-0P 685828-39-1P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 685828-40-4P, 4-[5-[(Morpholin-4-yl)methyl]-[1,3,4]oxadiazol-2-yl]piperidine-1-carboxylic acid tert-butyl ester 685828-41-5P, 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester 685828-42-6P, 4-[[4-Benzyl-5-(piperidin-4-yl)-4H-[1,2,4]triazol-3-yl]methyl]morpholine 685828-43-7P 685828-44-8P, 4-[(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)methyl]morpholine 685828-45-9P, 4-[[5-[4-(Pyridin-2-yl)piperazin-1-ylmethyl]-[1,3,4]oxadiazol-2-yl]methyl]morpholine 685828-46-0P, 4-[[5-[4-(Pyrimidin-2-yl)piperazin-1-ylmethyl]-[1,3,4]oxadiazol-2-yl]methyl]morpholine 685828-47-1P, 1-[[5-[1-(Pyrimidin-2-yl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl]methyl]piperidin-3-ol 685828-48-2P, (R)-2-[N'-[(3,4,5,6-Tetrahydro-2H-[1,2']bipyridin-4-yl)carbonyl]hydrazinocarbonyl]pyrrolidine-1-carboxylic acid tert-butyl ester 685828-50-6P, (R)-2-[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 685828-51-7P, (R)-4-[5-[[(Tetrahydrofuran-3-yl)oxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-52-8P, (S)-4-[5-[[(Tetrahydrofuran-3-yl)oxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-53-9P, [Methyl[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-ylmethyl]amino]acetic acid

tert-butyl ester 685828-54-0P, N'-[(3,4,5,6-Tetrahydro-2H-[1,2']bipyridin-4-yl)carbonyl]tetrahydrofuran-2-carboxylic hydrazide 685828-55-1P, 4-[5-(Tetrahydrofuran-2-yl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-56-2P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid N'-(2-tetrahydropyran-4-ylacetyl)hydrazide 685828-57-3P, 4-[5-(Tetrahydropyran-4-ylmethyl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-58-4P, 4-(5-Ethoxymethyl-[1,3,4]oxadiazol-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-59-5P, 4-[5-(2-Methoxyethoxymethyl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-60-8P, [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-ylmethoxy]acetic acid tert-butyl ester 685828-62-0P, 4-[5-[(Pyrazol-1-yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-63-1P 685828-64-2P, 4-[5-[([1,2,3]Triazol-1-yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-65-3P, 4-[5-(Pyridin-4-yloxymethyl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

IT 79-30-1, Isobutyryl chloride 98-91-9, Benzenecarbothioic acid 108-12-3, 3-Methylbutyryl chloride 108-86-1, Bromobenzene, reactions 109-02-4, 4-Methylmorpholine 109-09-1, 2-Chloropyridine 109-85-3 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 288-13-1, 1H-Pyrazole 288-35-7, 2H-[1,2,3]Triazole 541-16-2, tert-Butyl malonate 622-40-2, 2-(Morpholin-4-yl)ethanol 626-64-2, 4-Hydroxypyridine 770-17-2 870-46-2, Hydrazinecarboxylic acid tert-butyl ester 1722-12-9, 2-Chloropyrimidine 2627-86-3, ((S)-(-)-1-Phenylethyl)amine 3430-17-9, 2-Bromo-3-methylpyridine 3538-65-6, Butyric acid hydrazide 4595-60-2, 2-Bromopyrimidine 5332-73-0 5616-81-9 6602-54-6, 2-Chloro-3-cyanopyridine 6859-99-0, Piperidin-3-ol 14508-49-7, 2-Chloropyrazine 16874-33-2, Tetrahydrofuran-2-carboxylic acid 19810-31-2 26690-80-2, tert-Butyl N-(2-hydroxyethyl)carbamate 38291-82-6, Pentanoic acid hydrazide 40499-83-0, 3-Hydroxypyrrolidine 50595-15-8 51957-36-9, 1-(2-Pyrimidyl)piperidine 56613-80-0, (R)-(-)-2-Amino-2-phenylethanol 57260-71-6 65753-47-1, 2-Chloro-3-trifluoromethylpyridine 68654-52-4, 1-(2-Pyridyl)piperidine 86087-23-2, (S)-Tetrahydrofuran-3-ol 86087-24-3, (R)-Tetrahydrofuran-3-ol 101469-92-5, (3S)-3-Hydroxypyrrolidine-1-carboxylic acid tert-butyl ester 109431-87-0, (3R)-3-Hydroxypyrrolidine-1-carboxylic acid tert-butyl ester 111247-60-0, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic acid ethyl ester 120099-60-7 120099-61-8 130645-48-6, 2-Bromo-4-methylpyrimidine 154348-19-3, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid ethyl ester 187834-88-4, 4-(Hydrazinocarbonyl)piperidine-1-carboxylic acid tert-butyl ester 280110-69-2, 4-(5-Methyl-[1,3,4]oxadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 303144-44-7, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic acid 547716-11-0 685827-85-4 685828-49-3 685828-61-9, 4-[5-[(Methylsulfanyl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

=> b wpix;d all l4 tot
FILE 'WPIX' ENTERED AT 08:55:54 ON 22 SEP 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 20 SEP 2005 <20050920/UP>
MOST RECENT DERWENT UPDATE: 200560 <200560/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,

PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://thomsonderwent.com/coverage/latestupdates/ <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
http://thomsonderwent.com/support/userguides/ <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/
FOR DETAILS. <<<
'BIX BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2004-389824 [36] WPIX
DNC C2004-146105
TI New triazole compounds are arginine vasopressin V1a receptor antagonists useful to treat Alzheimer's disease, anorexia nervosa, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease and cataract.
DC B03
IN ARMOUR, R D; BAXTER, A D; BRYANS, J S; DACK, K N; JOHNSON, P S; LEWTHWAITE, R A; NEWMAN, J; RAWSON, D J; RYCKMANS, T; ARMOUR, D R
PA (PFIZ) PFIZER INC; (PFIZ) PFIZER LTD
CYC 104
PI WO 2004037809 A1 20040506 (200436)* EN 122 C07D401-04
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
US 2004162278 A1 20040819 (200455) A61K031-454 <--
AU 2003267791 A1 20040513 (200468) C07D401-04
EP 1558598 A1 20050803 (200551) EN C07D401-04
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR
BR 2003015676 A 20050906 (200560) C07D401-04
ADT WO 2004037809 A1 WO 2003-IB4587 20031014; US 2004162278 A1 **Provisional US 2002-428632P 20021122, US 2003-693327 20031024**; AU 2003267791 A1 AU 2003-267791 20031014; EP 1558598 A1 EP 2003-748487 20031014, WO 2003-IB4587 20031014; BR 2003015676 A BR 2003-15676 20031014, WO 2003-IB4587 20031014
FDT AU 2003267791 A1 Based on WO 2004037809; EP 1558598 A1 Based on WO 2004037809; BR 2003015676 A Based on WO 2004037809
PRAI **GB 2002-24919 20021025**
IC ICM A61K031-454; C07D401-04
ICS A61K031-4196; A61P007-00; A61P009-00; A61P013-00; A61P025-00; C07D401-06; C07D401-12; C07D401-14; C07D403-12; C07D405-14; C07D413-04; C07D413-06; C07D413-14
AB WO2004037809 A UPAB: 20040608
NOVELTY - Triazole compounds (I) and their salts and solvates are new.
DETAILED DESCRIPTION - Triazole compounds of formula (I) and their salts and solvates are new.
R1 = 1-6C alkyl, (CH2)C'-(3-8C cycloalkyl), (CH2)C'-W or

(CH2)c'-Z-(CH2)d-W;
W = 1-6C alkyl, 1-6C alkyloxy, CO2(1-6C alkyl), CONR4R5, NR4R5, het2, het3 or phenyl (optionally substituted with halo, CF3, OCF3, R3, OR3, CO2R3, CONR4R5, CN, SO2NR4R5 and/or NR3SO2Me);
Q = (CH2)b;
Q1 = (CHR7)a;
Z = O or S(O)g;
g = 0-2;
R2 = a phenyl (optionally fused to a 5-6 membered aryl or heterocyclic which may contain one or more heteroatoms of N, O or S (the phenyl and the optionally fused group is optionally substituted);
Ring A = 4-6 membered saturated heterocylic containing one N;
Ring B = phenyl or het1 (optionally substituted);
R7 = H, 1-6C alkyl, OR3, (CH2)e-R3 or (CH2)fO-(CH2)e-R3;
R3 = 1-6C alkyl (optionally substituted by Y), (CH2)g-(3-8C cycloalkyl), phenyl, benzyl, pyridyl, pyrimidyl or H; either
R4, R5 = H, 1-6C alkyl (optionally substituted with 1-6C alkyloxy), (CH2)gCO2-(1-6C alkyl), SO2Me, (CH2)g-(3-8C cycloalkyl), SO2Me, phenyl, benzyl, pyridyl or pyrimidyl; or
NR4R5 = heterocyclic from 3-8 atoms;
Y = NR4R5, het4 or phenyl (optionally substituted with halo, CF3, OCF3, R4, OR4, CO2R4, CONR4R5, CN, SO2NR4R5, NR4SO2Me or NR4R5);
het1 = 4-6 membered optionally saturated, heterocyclic containing one N (but which may also contain one or more O or S atoms);
het2 = 4-6 membered optionally saturated, heterocyclic containing at least one N (but which may also contain one or more O or S atoms) (optionally substituted);
het3 = 4-7 membered optionally saturated, heterocyclic containing one O (but which may also contain one or more N or S atoms) (optionally substituted);
het4 = 4-7 membered optionally saturated heterocyclic containing one N (but which may also contain one or more O or S atoms) (optionally substituted);
substituents for R2, Ring B, het1, het2, het3, het4 = halo, CF3, OCF3, R3, (CH2)e-SO2Me, (CH2)e-OR3, (CH2)e-CO2R3, (CH2)e-CONR4R5, (CH2)e-CN, (CH2)e-SO2NR4R5, (CH2)e-NR3SO2Me, (CH2)e-COR3, (CH2)e-OCOR3, (CH2)e-NHCOR3, (CH2)e-NR3COR6 or (CH2)eNR4R5;
R6 = 1-6C alkyl (optionally substituted by Y), (CH2)g'-(3-8C cycloalkyl), phenyl, benzyl, pyridyl, pyrimidyl or H;
a, b = 0-1;
c', d, e, g' = 0-4; and
f = 1-4.
Provided that:
(1) a + b cannot equal 0;
(2) when R1 is (CH2)c-Z-(CH2)d-W and W represents NR4R5 or any N linked heterocyclic group, then d must not be 0 or 1;
(3) when R2 is a phenyl group substituted by (CH2)eOR3, (CH2)e-CO2R3 or (CH2)eOCOR3, het1 and/or het2 are substituted by (CH2)eOR3, (CH2)e-CO2R3 or (CH2)eOCOR3, R7 is OR3 or (CH2)fO-(CH2)e-R3 and e is 0, W is phenyl substituted with OR3 or CO2R3, R3 is alkyl substituted with Y and Y is NR4R5 or an N-linked het3, then R3 must is 2-6C alkyl substituted with Y.
INDEPENDENT CLAIMS are also included for
(1) an intermediate oxadiazole of formula (II); and
(2) use of an arginine vasopressin V1a antagonist in combination with an oral contraceptive for the treatment of dysmenorrhoea.
ACTIVITY - Neuroprotective; Nootropic; Anabolic; Eating-Disorders-Gen.; Tranquilizer; Antiasthmatic; Antiarteriosclerotic; Cardiant; Cardiovascular-Gen.; Ophthalmological; CNS-Gen.; Cerebroprotective; Vasotropic; Hepatotropic; Endocrine-Gen.; Antidepressant; Antidiabetic; Analgesic; Gynecological; Antiinflammatory; Antiemetic; Cytostatic; Gastrointestinal-Gen.; Antidiuretic; Nephrotropic; Anorectic; Hypotensive; Tocolytic; Respiratory-Gen.; Hypnotic; Vulnerary; Thrombolytic; Antimicrobial; Uropathic.
MECHANISM OF ACTION - Arginine vasopressin V1a receptor antagonist. (I) were tested for their arginine vasopressin V1a receptor antagonistic

activity in CHO cells using V1a filter binding assay. The inhibitory constant (Ki) of 4-(4-benzyl-5-(4-methoxy-piperidin-1-ylmethyl)-4H-(1,2,4)triazol-3-yl)-3,4,5,6-tetrahydro-2H-(1,2')bipyridinyl was 4.5 nM.

USE - (I) are used to treat aggression, Alzheimer's disease, anorexia nervosa, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, cerebrovascular ischemia, cirrhosis, cognitive disorder, Cushing's disease, depression, diabetes mellitus, dysmenorrhea, edema, emesis, endometriosis, gastrointestinal disease, glaucoma, gynecological disease, heart disease, hypertension, hyponatremia, intrauterine growth retardation, ischemia, ischemic heart disease, lung tumor, micturition disorder, mittleschmerz, motion sickness, neoplasm, nephrotoxicity, non-insulin dependent diabetes, obesity, obsessive/compulsive disorder, ocular hypertension, premature ejaculation, premature labor, pulmonary disease, Raynaud's disease, renal disease, renal failure, male and female sexual dysfunction, sleep disorder, spinal cord injury, thrombosis, urogenital tract infection and urolithiasis (claimed).

ADVANTAGE - (I) are potent, stable and have a long duration of action, a broad range of activity and few side effects.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B06-H; B07-D13; B07-E04; B14-C03; B14-D01; B14-E05; B14-E11; B14-E12; B14-F02B; B14-F02D1; B14-F04; B14-F07; B14-H01B; B14-J01; B14-K01; B14-L06; B14-N03; B14-N07; B14-N10; B14-N14; B14-N16; B14-P02; B14-S04

=> b home
FILE 'HOME' ENTERED AT 08:55:58 ON 22 SEP 2005

=>

```
=> d his full

     (FILE 'HOME' ENTERED AT 08:52:27 ON 22 SEP 2005)

     FILE 'HCAPLUS' ENTERED AT 08:52:42 ON 22 SEP 2005
L1             1 SEA ABB=ON  PLU=ON  US2004162278/PN OR (US2003-693327# OR
                 GB2002-24919# OR US2002-428632#)/AP,PRN

     FILE 'REGISTRY' ENTERED AT 08:54:54 ON 22 SEP 2005

     FILE 'HCAPLUS' ENTERED AT 08:54:54 ON 22 SEP 2005
L2             TRA L1 1- RN :      221 TERMS

     FILE 'REGISTRY' ENTERED AT 08:54:54 ON 22 SEP 2005
L3           221 SEA ABB=ON  PLU=ON  L2

     FILE 'WPIX' ENTERED AT 08:55:04 ON 22 SEP 2005
L4             1 SEA ABB=ON  PLU=ON  US2004162278/PN OR (US2003-693327# OR
                 GB2002-24919# OR US2002-428632#)/AP,PRN

     FILE 'REGISTRY' ENTERED AT 08:59:20 ON 22 SEP 2005
L5            82 SEA ABB=ON  PLU=ON  L3 AND N2CNC/ES
L6               STR
L7             6 SEA SSS SAM L6
L8               STR L6
L9             0 SEA CSS SAM L8
L10           75 SEA CSS FUL L8
                 SAV TEM L10 SHI327F0/A
L11           69 SEA ABB=ON  PLU=ON  L10 AND L3

     FILE 'HCAPLUS' ENTERED AT 09:19:52 ON 22 SEP 2005
L12            4 SEA ABB=ON  PLU=ON  L10

     FILE 'HCAOLD' ENTERED AT 09:20:44 ON 22 SEP 2005
L13            0 SEA ABB=ON  PLU=ON  L10

     FILE 'USPATFULL, USPAT2' ENTERED AT 09:20:50 ON 22 SEP 2005
L14            5 SEA ABB=ON  PLU=ON  L10

     FILE 'HCAPLUS' ENTERED AT 09:21:27 ON 22 SEP 2005
                 SEL AN 2 3 L12
L15            2 SEA ABB=ON  PLU=ON  ("140:391283"/AN OR "141:225517"/AN OR
                 "2004:370921"/AN OR "2004:718543"/AN) AND L12
L16            2 SEA ABB=ON  PLU=ON  L12 NOT L15

     FILE 'USPATFULL, USPAT2' ENTERED AT 09:23:06 ON 22 SEP 2005
                 SEL AN 1 3 4 L14
L17            3 SEA ABB=ON  PLU=ON  ("2004:209844"/AN OR "2004:240276"/AN OR
                 "2005:31373"/AN) AND L14
L18            2 SEA ABB=ON  PLU=ON  L14 NOT L17

=> b reg

FILE 'REGISTRY' ENTERED AT 09:24:04 ON 22 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 SEP 2005  HIGHEST RN 863636-50-4
DICTIONARY FILE UPDATES:  21 SEP 2005  HIGHEST RN 863636-50-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

**********
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
**********

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que sta l10
L8 STR




REP G1=(0-1) C
REP G2=(0-1) 12
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 6
CONNECT IS M1 RC AT 11
CONNECT IS M1 RC AT 12
DEFAULT MLEVEL IS ATOM
GGCAT IS SAT AT 8
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 8

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L10 75 SEA FILE=REGISTRY CSS FUL L8

100.0% PROCESSED 351225 ITERATIONS 75 ANSWERS
SEARCH TIME: 00.00.09

=> b hcap
FILE 'HCAPLUS' ENTERED AT 09:24:10 ON 22 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

| | | |
|---|---|---|
| | | C07D498-04; C07D401-04; C07D413-14; C07D513-04; C07D249-00; C07D243-00; C07D267-00 |
| WO 2004074291 | ECLA | C07D401/04+213+211; C07D401/04+239B+211; C07D413/14+271+213+211; C07D413/14+271+239B+211; C07D487/04+249C+243C; C07D487/04+249C+245C; C07D498/04+267C+249C; C07D498/04+273C+249C; C07D513/04+281C+249C |
| US 2004186091 | NCL | 514/210.210 |
| | ECLA | C07D401/04+213+211; C07D401/04+239B+211; C07D413/14+271+213+211; C07D413/14+271+239B+211; C07D487/04+249C+243C; C07D487/04+249C+245C; C07D498/04+267C+249C; C07D498/04+273C+249C; C07D513/04+281C+249C |
| NL 1025527 | ECLA | C07D401/04+213+211; C07D401/04+239B+211; C07D413/14+271+213+211; C07D413/14+271+239B+211; C07D487/04+249C+243C; C07D487/04+249C+245C; C07D498/04+267C+249C; C07D498/04+273C+249C; C07D513/04+281C+249C |
| US 2005026810 | NCL | 514/001.000 |
| | ECLA | C07D401/14R+249B+213+211 |

OS MARPAT 141:225517
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein V = -(CH2)d(O)e-, -CO-, -CH(alkyl)-; W = O, S(:O)a, NH and derivs.; X, Y = independently H, alkyl, halo, OH, CF3, OCF3, alkoxy, Z = -(CH2)f(O)g-, -CO-, -CH(alkyl)-; A = 4-7 membered (un)substitued saturated N-containing heterocycle; B = Ph, (un)substitued saturated N-containing heterocycle; a = 0-2; e, g = 0-1; d, f = 1-2; and their pharmaceutically acceptable derivs.] were prepared as vasopressin receptor V1a antagonists for the treatment of dysmenorrhea. Thus, amination of chloride II (preparation given) with 2-aminomethyl-4-chlorophenylamine (preparation given), cyclization of the aminooxadiazole, and reaction of amine with dimethylsulphamoyl chloride gave the triazole III. III displayed a Ki = 0.24 nM in a V1a filter binding assay.

ST triazole prepn V1a antagonist dysmenorrhea

IT Blood vessel, disease
(Raynaud's phenomenon, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Vasopressin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(V1a, antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Heart, disease
(angina pectoris, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Uterus, disease
(endometriosis, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Heart, disease
(failure, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Embryo, animal, disease
(fetus, intrauterine growth retardation, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Sexual behavior
(premature ejaculation, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Parturition

(premature, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Anti-inflammatory agents
Antianginal agents
Antiemetics
Antihypertensives
Antirheumatic agents
Anxiolytics
Cardiovascular agents
Diuretics
Human
(preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Dysmenorrhea
(treatment of primary and secondary; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Anxiety
Atherosclerosis
Cardiovascular system, disease
Dysmenorrhea
Edema
Hypertension
Inflammation
Motion sickness
Preeclampsia
Rheumatoid arthritis
Vomiting
(treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 748805-32-5P 748805-33-6P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 748804-60-6P, 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748804-63-9P 748804-71-9P, 8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748804-79-7P, 4-(8-Chloro-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulen-1-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-carbonitrile 748804-98-0P, 2-Chloro-1-[8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]ethanone 748805-02-9P 748805-09-6P, 8-Chloro-5-[(pyrrolidin-(2S)-2-yl)methyl]-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748805-13-2P 748805-14-3P, 5-(Azetidin-3-yl)-8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748805-15-4P, 8-Chloro-5-(pyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748805-20-1P 748805-66-5P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-triazabenzo[e]azulene 748806-39-5P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 748804-61-7P, 5-Methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748804-62-8P, 1-[1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]ethanone 748804-64-0P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene trihydrochloride 748804-65-1P, 8-Chloro-5-isopropyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene trihydrochloride

748804-66-2P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5-(tetrahydropyran-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748804-67-3P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]ethanone dihydrochloride 748804-68-4P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]cyclopropylmethanone dihydrochloride 748804-69-5P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]-2,2-dimethylpropan-1-one dihydrochloride 748804-70-8P, 8-Chloro-5-methanesulfonyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748804-72-0P, 8-Chloro-5-methyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748804-73-1P, 8-Chloro-5-isopropyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748804-74-2P, 8-Chloro-5-methanesulfonyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748804-75-3P, [8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]cyclopropylmethanone 748804-76-4P, 1-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]-2,2-dimethylpropan-1-one 748804-77-5P, 1-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]ethanone 748804-78-6P, 8-Chloro-1-(6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene 748804-80-0P, 4-(8-Chloro-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulen-1-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-carboxylic acid amide 748804-81-1P, 13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748804-82-2P, 1-[13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaen-8-yl]ethanone 748804-83-3P, 13-Chloro-8-methyl-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748804-84-4P, 3-[1-(Pyrimidin-2-yl)piperidin-4-yl]-8-oxa-2,4,5-triazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748804-85-5P, 8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene 748804-86-6P, 13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-8-oxa-2,4,5-triazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748804-87-7P, 3-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-8-oxa-2,4,5-triazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene dihydrochloride 748804-88-8P, 8-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene 748804-89-9P, 7-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene dihydrochloride 748804-90-2P, 1-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene 748804-91-3P, 8-Methoxy-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene dihydrochloride 748804-92-4P, 8-Fluoro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene 748804-93-5P, 8,9-Difluoro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene dihydrochloride 748804-94-6P, 9-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene dihydrochloride 748804-95-7P, 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-8-trifluoromethoxy-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene 748804-96-8P, 8-Methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene 748804-99-1P, 2-(Azetidin-1-yl)-1-[8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]ethanone 748805-00-7P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]-2-(pyrrolidin-1-yl)ethanone 748805-01-8P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]pyrrolidin-3-ylmethanone trihydrochloride 748805-03-0P 748805-04-1P 748805-05-2P 748805-06-3P 748805-07-4P 748805-08-5P 748805-10-9P 748805-11-0P 748805-12-1P 748805-16-5P, 8-Chloro-5-(piperidin-4-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-

yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene trihydrochloride 748805-17-6P, 8-Chloro-5-[1,4]oxazepan-6-yl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene trihydrochloride 748805-18-7P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]morpholin-4-ylmethanone 748805-19-8P 748805-21-2P 748805-22-3P 748805-23-4P, [2-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]ethyl]dimethylamine trihydrochloride 748805-24-5P, 8-Chloro-5-[2-(pyrrolidin-1-yl)ethyl]-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene trihydrochloride 748805-25-6P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]acetic acid methyl ester 748805-26-7P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]-3-methoxypropan-1-one 748805-27-8P 748805-28-9P, 8-Chloro-5-(1-methylpyrrolidin-(2S)-2-ylmethyl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene trihydrochloride 748805-29-0P 748805-30-3P 748805-31-4P 748805-34-7P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]((2S)-1-methylpyrrolidin-2-yl)methanone 748805-35-8P 748805-36-9P 748805-37-0P 748805-38-1P 748805-39-2P 748805-40-5P 748805-41-6P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl](tetrahydropyran-4-yl)methanone 748805-42-7P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl][1-(methyl)piperidin-4-yl]methanone 748805-43-8P, 8-Chloro-5-(1-methylazetidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748805-44-9P 748805-45-0P 748805-46-1P 748805-47-2P 748805-48-3P, 8-Chloro-5-(1-methylpyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748805-49-4P, 8-Chloro-5-(1-isopropylpyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene trihydrochloride 748805-50-7P, 2-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]ethanol 748805-51-8P, 8-Chloro-5-(2-methoxyethyl)-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748805-52-9P, 8-Chloro-5-(pyrimidin-2-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748805-53-0P, 8-Chloro-5-(pyrimidin-4-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748805-54-1P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulene-5-carboxaldehyde 748805-55-2P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulene-5-sulfonic acid dimethylamide 748805-56-3P, 8-Chloro-5-[(pyridin-2-yl)methyl]-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748805-57-4P 748805-58-5P 748805-59-6P, 8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenzo[e]azulene-5-sulfonic acid dimethylamide 748805-60-9P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4,5-dihydro-2,3,5,10b-tetraazabenzo[e]azulen-6-one 748805-61-0P, 13-Chloro-9-methyl-3-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-2,4,5,9-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748805-62-1P, 13-Chloro-8-methyl-3-[1-(pyrimidin-2-yl)piperidin-4-yl]-2,4,5,8-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748805-63-2P, 8-Chloro-5,6-dimethyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 748805-64-3P, 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-8-trifluoromethyl-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene 748805-65-4P, 10-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-6,7-dihydro-4H-5,8-dioxa-2,3,12b-triazabenzo[a]cyclopenta[c]cyclononene 748805-67-6P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-triazabenzo[e]azulene 5-oxide 748805-68-7P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-

triazabenzo[e]azulene 5,5-dioxide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 7440-23-5, Sodium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hypernatremia; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 748804-97-9P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]-2-dimethylaminoethanone 748806-17-9P 748806-18-0P 748806-19-1P 748806-20-4P 748806-21-5P 748806-22-6P 748806-23-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate, V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 19178-37-1P, 2-Amino-5-chloro-N-methylbenzamide 22908-49-2P, 2-(2-Methylaminoethyl)phenylamine 37585-16-3P, (2-Amino-4-chlorophenyl)methanol 39885-08-0P 55414-72-7P, (2-Amino-5-methoxyphenyl)methanol 65826-89-3P, 2-(2-Amino-5-chlorophenyl)ethanol 83265-56-9P, 2-Amino-5-trifluoromethoxybenzoic acid 108047-39-8P 154348-19-3P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid ethyl ester 215124-42-8P, (2-Amino-5-trifluoromethoxyphenyl)methanol 258850-08-7P, 7-Chloro-1,3,4,5-tetrahydrobenzo[e][1,4]diazepin-2-one 681464-03-9P, N-[2-(2-Acetylaminoethyl)phenyl]acetamide 685828-02-8P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-03-9P, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685828-06-2P, N'-(2-Chloroacetyl)-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-07-3P, N'-(2-Chloroacetyl)-1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685828-08-4P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-09-5P, 2-[4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine 685828-38-0P, 4-[[N'-(2-Chloroacetyl)hydrazino]carbonyl]piperidine-1-carboxylic acid tert-butyl ester 685828-39-1P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 748805-69-8P, Acetic acid 2-(2-acetylamino-5-chlorophenyl)ethyl ester 748805-70-1P, [2-[[[[5-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-yl]methyl]amino]methyl]phenyl]amine 748805-71-2P, [4-Chloro-2-[[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-yl]methyl]amino]methyl]phenyl]amine 748805-72-3P, [4-Chloro-2-[[[[5-[1-(pyrimidin-2-yl)piperidin-4-yl][1,3,4]oxadiazol-2-yl]methyl]amino]methyl]phenyl]amine 748805-73-4P, [2-[[[5-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-74-5P, [3-Chloro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-75-6P, [5-Chloro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-76-7P, [4-Methoxy-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-77-8P, [4-Chloro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-78-9P, [2-[2-[[5-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]ethyl]phenyl]amine 748805-79-0P, [4-Chloro-2-[2-[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]ethyl]phenyl]amine 748805-80-3P, [4-Chloro-2-[[[5-[1-(pyrimidin-2-yl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-81-4P, [2-[2-[[5-[1-(Pyrimidin-2-yl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl]methoxy]ethyl]phenyl]amine 748805-82-5P, 4-[5-[(2-Amino-5-chlorobenzyloxy)methyl]-[1,3,4]oxadiazol-2-yl]piperidine-1-carboxylic acid tert-butyl ester 748805-83-6P, 4-(8-Chloro-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulen-1-yl)piperidine-1-carboxylic acid tert-butyl ester 748805-84-7P, 8-Chloro-1-(piperidin-4-

yl)-4H,6H-5-oxa-2,3,10b-triazabenzo[e]azulene 748805-85-8P, (2-Amino-5-fluorophenyl)methanol 748805-86-9P, [4-Fluoro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-87-0P, (2-Amino-4,5-difluorophenyl)methanol 748805-88-1P, [4,5-Difluoro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-89-2P, [2-[[[5-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]-4-trifluoromethoxyphenyl]amine 748805-90-5P, [4-Methyl-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-91-6P, N-[2-(2-Acetylaminoethyl)-4-chlorophenyl]acetamide 748805-92-7P, [2-(2-Aminoethyl)-4-chlorophenyl]amine dihydrochloride 748805-93-8P, [4-Chloro-2-[2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methyl]amino]ethyl]phenyl]amine 748805-94-9P 748805-95-0P 748805-96-1P, 6-Methylene-[1,4]oxazepane-4-carboxylic acid tert-butyl ester 748805-97-2P, 6-Oxo-[1,4]oxazepane-4-carboxylic acid tert-butyl ester 748805-98-3P, 2-(1-Methylaminoethyl)phenylamine 748805-99-4P, N-[2-[2-[(Acetyl)(methyl)amino]ethyl]phenyl]acetamide 748806-00-0P, N-[2-[1-[(Acetylmethyl)amino]ethyl]phenyl]acetamide 748806-01-1P, N-[2-[2-[(Acetyl)(methyl)amino]ethyl]-4-chlorophenyl]acetamide 748806-02-2P, N-[2-[1-[(Acetyl)(methyl)amino]ethyl]-4-chlorophenyl]acetamide 748806-03-3P, [4-Chloro-2-(2-methylaminoethyl)phenyl]amine 748806-04-4P, 4-Chloro-2-[1-(methylamino)ethyl]phenylamine 748806-05-5P, 2-(5-Chloro-2-nitrophenoxy)ethanol 748806-06-6P, 3-[(5-Chloro-2-nitrobenzyl)amino]propionic acid methyl ester 748806-07-7P, 3-[(5-Chloro-2-nitrobenzyl)(methyl)amino]propionic acid methyl ester 748806-08-8P, 2-(2-Amino-5-chlorophenoxy)ethanol 748806-09-9P, 3-[(2-Amino-5-chlorobenzyl)(methyl)amino]propionic acid methyl ester 748806-10-2P, 3-[(2-Amino-5-chlorobenzyl)(methyl)amino]propionic acid dihydrochloride 748806-11-3P, Methyl[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-yl]methyl]amine 748806-12-4P, [4-Chloro-2-[2-[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]ethoxy]phenyl]amine 748806-13-5P, 2-Amino-5-chloro-N-methyl-N-[[(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methyl]benzamide 748806-14-6P 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine 748806-16-8P, tert-Butyl 3-[[8-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,y10b-tetraazabenzo[e]azulen-5-yl]carbonyl]pyrrolidine-1-carboxylate 748806-24-8P, 3-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]azetidine-1-carboxylic acid tert-butyl ester 748806-25-9P, 3-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 748806-26-0P, 4-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]piperidine-1-carboxylic acid tert-butyl ester 748806-27-1P, 6-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-10b-2,3,5,10b-tetraazabenzo[e]azulen-5-yl]-[1,4]oxazepane-4-carboxylic acid 748806-28-2P, 8-Chloro-5-methyl-3,4,5,6-tetrahydro-1H-benzo[b][1,5]diazocin-2-one 748806-29-3P, 8-Chloro-5-methyl-3,4,5,6-tetrahydro-1H-benzo[b][1,5]diazocine-2-thione 748806-30-6P, 8-Chloro-5-methyl-2-methylsulfanyl-3,4,5,6-tetrahydrobenzo[b][1,5]diazocine 748806-31-7P, (2-Amino-5-chlorobenzylamino)acetic acid tert-butyl ester 748806-32-8P, 7-Chloro-4-methyl-1,3,4,5-tetrahydrobenzo[e][1,4]diazepin-2-one 748806-33-9P, 7-Chloro-4-methyl-1,3,4,5-tetrahydrobenzo[e][1,4]diazepine-2-thione 748806-34-0P, [(5-Chloro-2-nitrobenzyl)sulfanyl]acetic acid 748806-35-1P, 2-Chloro-5,9-dihydro-8-thia-5-azabenzocyclohepten-6-one 748806-36-2P, 2-Chloro-5,9-dihydro-8-thia-5-azabenzocycloheptene-6-thione 748806-37-3P, (2-Amino-5-chlorobenzyl)methylamine 748806-38-4P, (2-Amino-5-chlorobenzyl)(methyl)[[5-[1-(pyridin-2-yl)piperidin-4-yl]-1,3,4-oxadiazol-2-yl]methyl]amine 748806-40-8P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-

tetraazabenzo[e]azulene dibesylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 89-77-0, 2-Amino-4-chlorobenzoic acid 96-32-2, Methyl bromoacetate 107-59-5 109-02-4, 4-Methylmorpholine 109-04-6, 2-Bromopyridine 123-75-1, Pyrrolidine, reactions 446-08-2, 2-Amino-5-fluorobenzoic acid 503-29-7, Azetidine 551-93-9, o-Aminoacetophenone 635-21-2, 5-Chloroanthranilic acid 700-37-8, 4-Chloro-2-fluoronitrobenzene 1118-68-9, N,N-Dimethylglycine 1121-60-4, 2-Pyridinecarboxaldehyde 1126-09-6, Ethyl isonipecotate 1722-12-9, 2-Chloropyrimidine 1871-57-4, 3-Chloro-2-chloromethyl-1-propene 2148-56-3, 2-Amino-6-chlorobenzoic acid 2544-06-1, 3-Methoxypropionic acid 3196-73-4, β-Alanine methyl ester hydrochloride 3282-30-2, 2,2-Dimethylpropionyl chloride 4023-34-1, Cyclopropanecarbonyl chloride 4403-69-4 4743-17-3, 5-Chloroisatoic anhydride 5337-03-1, Tetrahydro-4-pyrancarboxylic acid 5344-90-1, (2-Aminophenyl)methanol 5922-60-1, 2-Amino-5-chlorobenzonitrile 6269-99-4, N-[2-(2-Hydroxyethyl)phenyl]acetamide 6482-24-2, 2-Bromo-1-methoxyethane 6705-03-9, 2-Amino-5-methoxybenzoic acid 7568-92-5, 2-(2-Aminophenyl)ethanol 14788-12-6, 3-Dimethylaminopropionic acid hydrochloride 15159-40-7, Morpholinocarbonyl chloride 17180-93-7, 4-Chloropyrimidine 26690-80-2, (2-Hydroxyethyl)carbamic acid tert-butyl ester 29943-42-8, Tetrahydropyran-4-one 31577-25-0, 2-(Bromomethyl)-4-chloro-1-nitrobenzene 33100-16-2, N-Methyl-N-[2-(2-nitrophenyl)ethyl]amine 33252-29-8, 6-Chloropyridine-2-carbonitrile 34897-84-2, (2-Amino-5-methylphenyl)methanol 37585-25-4, (2-Amino-5-chlorophenyl)methanol 39890-95-4, 2-Chloro-6-trifluoromethylpyridine 48108-93-6, 2-(2-Aminoethyl)phenylamine 71985-80-3, 1-Methylpiperidine-4-carboxylic acid hydrochloride 79099-07-3, tert-Butyl 4-oxo-1-piperidinecarboxylate 83506-93-8, 2-Amino-4,5-difluorobenzoic acid 101385-93-7, tert-Butyl 3-oxo-1-pyrrolidinecarboxylate 111247-60-0, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic acid ethyl ester 135072-32-1, 4-Phenylmethyl-2-morpholinecarboxylic acid ethyl ester 169037-23-4, 5-Trifluoromethoxy-1H-indole-2,3-dione 187834-88-4, 4-(Hydrazinocarbonyl)piperidine-1-carboxylic acid tert-butyl ester 212650-43-6, 4-(tert-Butoxycarbonyl)morpholine-3-carboxylic acid 220107-65-3 398489-26-4, 3-Oxoazetidine-1-carboxylic acid tert-butyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 14127-61-8, Calcium (II) ion, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(release of intracellular; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Albright, J; WO 9749707 A1 1997 HCAPLUS
(2) American Home Prod; WO 9820011 A 1998 HCAPLUS
(3) Ashwood, M; JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY 1989, 11, HCAPLUS
(4) Breslin, H; BIOORGANIC & MEDICINAL CHEMISTRY 1999, V7(11), P2427 HCAPLUS
(5) Goel; SYNTHESIS 1987, 2, P162 HCAPLUS
(6) Guaciaro, M; US 5438035 A 1995 HCAPLUS
(7) Merck Sharp And Dohme Ltd; EP 0362942 A2 1990 HCAPLUS
(8) Ortho McNeil Pharm Inc; WO 0043398 A 2000 HCAPLUS
(9) Wyeth; WO 02083678 A 2002 HCAPLUS

IT 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

RN 748806-15-7 HCAPLUS
CN 4H-1,2,4-Triazole-3-methanamine, N-[1-(2-amino-5-chlorophenyl)ethyl]-4-(4-chlorophenyl)-N-methyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:370921 HCAPLUS
DN 140:391283
ED Entered STN: 07 May 2004
TI Preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea
IN Armour, Robert Duncan; Baxter, Andrew Douglas; Bryans, Justin Stephen; Dack, Kevin Neil; Johnson, Patrick Stephen; Lewthwaite, Russell Andrew; Newman, Julie; Rawson, David James; Ryckmans, Thomas
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D401-04
ICS C07D401-06; C07D401-14; C07D413-04; C07D413-06; C07D413-14; A61K031-4196; A61P009-00; A61P007-00; A61P013-00; A61P025-00; C07D403-12; C07D401-12; C07D405-14
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2004037809 | A1 | 20040506 | WO 2003-IB4587 | 20031014 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2502932 | AA | 20040506 | CA 2003-2502932 | 20031014 |
| | EP 1558598 | A1 | 20050803 | EP 2003-748487 | 20031014 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | US 2004162278 | A1 | 20040819 | US 2003-693327 | 20031024 |
| PRAI | GB 2002-24919 | A | 20021025 | | |
| | US 2002-428632P | P | 20021122 | | |
| | WO 2003-IB4587 | W | 20031014 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|

| | | |
|---|---|---|
| WO 2004037809 | ICM | C07D401-04 |
| | ICS | C07D401-06; C07D401-14; C07D413-04; C07D413-06; C07D413-14; A61K031-4196; A61P009-00; A61P007-00; A61P013-00; A61P025-00; C07D403-12; C07D401-12; C07D405-14 |
| WO 2004037809 | ECLA | C07D401/04+249B+211; C07D401/06+249B+211; C07D401/12+249B+213; C07D401/14+249B+213+211; C07D401/14+249B+239B+211; C07D401/14+249B+241B+211; C07D401/14+249B+213+211+211; C07D401/14+249B+213+211+207; C07D401/14+249B+239B+211+211; C07D401/14+249B+249+213+211; C07D401/14+249B+213+213+211; C07D403/12+249B+239B; C07D405/14+307B+249B+213+211; C07D405/14+309+249B+213+211; C07D413/04+271+211; C07D413/06+271+211; C07D413/14+271+213+211; C07D413/14+271+213+211+211; C07D413/14+271+239B+211 |
| CA 2502932 | ECLA | C07D401/04+249B+211; C07D401/06+249B+211; C07D401/12+249B+213; C07D401/14+249B+213+211; C07D401/14+249B+213+211+207; C07D401/14+249B+213+211+211; C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211; C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211; C07D401/14+249B+249+213+211; C07D403/12+249B+239B; C07D405/14+307B+249B+213+211; C07D405/14+309+249B+213+211; C07D413/04+271+211; C07D413/06+271+211; C07D413/14+271+213+211; C07D413/14+271+213+211+211; C07D413/14+271+239B+211 |
| EP 1558598 | ECLA | C07D401/04+249B+211; C07D401/06+249B+211; C07D401/12+249B+213; C07D401/14+249B+213+211; C07D401/14+249B+213+211+207; C07D401/14+249B+213+211+211; C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211; C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211; C07D401/14+249B+249+213+211; C07D403/12+249B+239B; C07D405/14+307B+249B+213+211; C07D405/14+309+249B+213+211; C07D413/04+271+211; C07D413/06+271+211; C07D413/14+271+213+211; C07D413/14+271+213+211+211; C07D413/14+271+239B+211 |
| US 2004162278 | NCL | 514/210.200 |
| | ECLA | C07D401/04+249B+211; C07D401/06+249B+211; C07D401/12+249B+213; C07D401/14+249B+213+211; C07D401/14+249B+213+211+207; C07D401/14+249B+213+211+211; C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211; C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211; C07D401/14+249B+249+213+211; C07D403/12+249B+239B; C07D405/14+307B+249B+213+211; C07D405/14+309+249B+213+211; C07D413/04+271+211; C07D413/06+271+211; C07D413/14+271+213+211; C07D413/14+271+213+211+211; C07D413/14+271+239B+211 |

OS MARPAT 140:391283
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = cyclo/alkyl, (CH2)cW, (CH2)cZ(CH2)dW; W = alkyl, alkyloxy, CONH2 and derivs., NH2 and derivs., (un)substituted Ph, etc.; Z = O or S(O)g; g = 0-2; R2 = Ph optionally fused to a 5- or 6-membered aryl or heteroaryl; Y = (CHR3)a; R3 = independently H, alkyl, OH and derivs., etc.; X = (CH2)b; a, b = independently 0-1; c, d = 0-4; A = 4-, 5- or 6-membered saturated heterocyclyl, B = (un)substituted Ph, 4-, 5-, or 6-membered (un)saturated heterocyclyl; their pharmaceutically acceptable

salts and solvates] were prepared as vasopressin receptor V1a antagonists for the treatment of dysmenorrhea. Thus, reacting oxadiazole II (preparation given) with (S)-1-phenylethylamine in the presence of anhydrous MgCl2 at 150° gave triazole III. I showed Ki values < 500 nM in a V1a filter binding assay.

ST triazole prepn V1a antagonist dysmenorrhea

IT Blood vessel, disease
(Raynaud's phenomenon, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Vasopressin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(V1a, antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Behavior
(aggressive; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Appetite
(anorexia nervosa, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Ischemia
(cardiac, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Nervous system, disease
(central; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Mental disorder
(cognitive, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Mental disorder
(depression, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Urogenital tract
(disease, infection, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Sexual behavior
(disorder, treatment of male and female; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Cognition
(disorder, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Uterus, disease
(endometriosis, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Heart, disease
Kidney, disease
(failure, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Reproductive tract, disease
(female, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Embryo, animal, disease
(fetus, intrauterine growth retardation, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Spinal cord, disease
(injury, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Heart, disease
(ischemia, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Diabetes mellitus
(non-insulin-dependent, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Mental disorder

(obsession-compulsion, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Contraceptives
Drug delivery systems
(oral; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Sexual behavior
(premature ejaculation, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Parturition
(premature, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Anti-Alzheimer's agents
Anti-ischemic agents
Antiasthmatics
Antidepressants
Antidiabetic agents
Antiemetics
Antiglaucoma agents
Antihypertensives
Antiobesity agents
Antitumor agents
Anxiolytics
Cardiovascular agents
Cognition enhancers
Diuretics
Human
Hypnotics and Sedatives
Thrombolytics
(preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Injury
(spinal cord, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Ischemia
(treatment of cerebrovascular; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
IT Alzheimer's disease
Anxiety
Asthma
Atherosclerosis
Calculi, urinary
Cardiovascular system, disease
Cataract
Cirrhosis
Cushing's syndrome
Diabetes mellitus
Digestive tract, disease
Dysmenorrhea
Edema
Glaucoma (disease)
Heart, disease
Hypertension
Ischemia
Kidney
Kidney, disease
Lung, disease
Lung, neoplasm
Micturition
Motion sickness
Neoplasm
Nervous system agents
Obesity
Sleep disorders
Thrombosis
Vomiting

(treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Infection
(urogenital, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT **685827-43-4P**, 4-[4-Benzyl-5-[4-(methanesulfonyl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-47-8P**, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3'-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(V1A receptor antagonist, V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT **685827-36-5P**, 4-[4-(3-Chlorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-69-4P**, 4-[4-Benzyl-5-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(V1A receptor antagonist; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

IT **685827-26-3P**, Benzyl 4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazine-1-carboxylate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(V1a receptor antagonist, intermediate; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT **685826-99-7P**, (S)-4-[5-Butyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-00-3P**, 2-[4-(4-Benzyl-5-isobutyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-01-4P**, (S)-4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-02-5P**, 4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-03-6P**, 2-[4-(4-Benzyl-5-isopropyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-04-7P**, 2-[4-(4-Benzyl-5-cyclopropyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-05-8P**, (S)-2-[4-[5-Methyl-4-(1-phenylpropyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-06-9P**, 2-[4-(4-Benzyl-5-propyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-07-0P**, 2-[4-[4-Benzyl-5-(2-chlorophenoxymethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-08-1P**, 2-[4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-09-2P**, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-10-5P**, 2-[4-[4-Benzyl-5-(4-fluorophenoxymethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-11-6P**, 2-[4-[5-Methyl-4-(3-methylbenzyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-12-7P**, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-ylmethyl]piperidin-1-yl]pyrimidine **685827-13-8P**, 2-[4-[4-(3-Fluorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-14-9P**, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-15-0P**, 4-[4-Benzyl-5-[(benzyloxy)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-16-1P**, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-17-2P**, (R)-2-[3-Methyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-[1,2,4]triazol-4-yl]-2-phenylethanol **685827-18-3P**, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]-4-methylpyrimidine **685827-19-4P**, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-20-7P**, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-1-phenylpiperidine

685827-21-8P, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrazine 685827-22-9P, 4-(4-Benzyl-5-[(piperidin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-23-0P, (S)-4-[4-(1-Phenylethyl)-5-[(piperidin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-24-1P, 4-[4-Benzyl-5-(4-methoxypiperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-25-2P, (S)-4-[5-(4-Methoxypiperidin-1-ylmethyl)-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-27-4P, 4-[4-Benzyl-5-[[2-(morpholin-4-yl)ethoxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-28-5P, 4-[4-Benzyl-5-((3R)-3-methoxypyrrolidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-29-6P 685827-30-9P 685827-31-0P 685827-32-1P 685827-33-2P 685827-34-3P 685827-35-4P 685827-37-6P, N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]acetamide 685827-38-7P, 2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethylamine 685827-39-8P, N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]ethylamine 685827-40-1P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)amine 685827-41-2P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)amine 685827-42-3P, 1-[4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazin-1-yl]ethanone 685827-44-5P, N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]methanesulfonamide 685827-45-6P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)methylamine 685827-46-7P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)methylamine 685827-48-9P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-49-0P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carbonitrile 685827-50-3P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carboxylic acid amide 685827-51-4P, (S)-4-[[4-(1-Phenylethyl)-5-[4-(pyridin-2-yl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]methyl]morpholine trihydrochloride 685827-52-5P, (S)-4-[[4-(1-Phenylethyl)-5-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]-4H-[1,2,4]triazol-3-yl]methyl]morpholine trihydrochloride 685827-53-6P, 1-[[4-Benzyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]piperidin-3-ol 685827-54-7P, (R)-2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 685827-55-8P, (R)-4-[4-Benzyl-5-[[(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-56-9P, (S)-4-[4-Benzyl-5-[[(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-57-0P, [[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]methylamino]acetic acid tert-butyl ester 685827-58-1P, 4-[4-Benzyl-5-(tetrahydropyran-4-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-59-2P, 4-[4-Benzyl-5-(tetrahydrofuran-2-yl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-60-5P, 4-[4-Benzyl-5-(ethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-61-6P, 4-[4-Benzyl-5-(2-methoxyethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-62-7P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]acetic acid tert-butyl ester 685827-63-8P, N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-

ylmethoxy]acetamide **685827-64-9P**, 4-[4-Benzyl-5-[(methylsulfanyl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-65-0P**, 4-(4-Benzyl-5-[(pyrazol-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-66-1P**, 4-(4-Benzyl-5-[([1,2,3]triazol-2-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-67-2P, 4-(4-Benzyl-5-[1,2,3]triazol-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-68-3P**, 4-[4-Benzyl-5-(pyridin-4-yloxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 7440-23-5, Sodium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyponatremia; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 474707-30-7P, (3R)-3-Methoxypyrrolidine hydrochloride 549532-08-3P, (3R)-3-Methoxypyrrolidine-1-carboxylic acid tert-butyl ester 550371-69-2P, (3S)-3-Methoxypyrrolidine-1-carboxylic acid tert-butyl ester 685827-70-7P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid 685827-71-8P, N'-Butyryl-1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685827-72-9P 685827-73-0P 685827-74-1P 685827-75-2P 685827-76-3P 685827-77-4P 685827-78-5P 685827-79-6P 685827-80-9P, N'-Pentanoyl-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685827-81-0P, N'-Acetyl-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685827-82-1P, N'-[2-(Morpholin-4-yl)acetyl]-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685827-83-2P, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide monohydrochloride 685827-84-3P, N'-(3-Methylbutyryl)-1-(pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685827-86-5P, 2-[4-(5-Isobutyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine 685827-87-6P 685827-88-7P 685827-89-8P 685827-90-1P 685827-91-2P 685827-92-3P 685827-93-4P 685827-94-5P 685827-95-6P 685827-96-7P 685827-97-8P, 2-[4-(5-Methyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine 685827-98-9P, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester 685827-99-0P, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidine monohydrochloride 685828-00-6P, 4-[(5-Methyl-[1,3,4]oxadiazol-2-yl)methyl]piperidine monohydrochloride 685828-01-7P, 2-[4-[(5-Methyl-[1,3,4]oxadiazol-2-yl)methyl]piperidin-1-yl]pyrimidine 685828-02-8P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-03-9P, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685828-04-0P, N'-(2-Benzyloxyacetyl)-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-05-1P, 4-[5-[(Benzyloxy)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-06-2P, N'-(2-Chloroacetyl)-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-07-3P, N'-(2-Chloroacetyl)-1-(pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685828-08-4P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-09-5P, 2-[4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine 685828-10-8P, 4-[5-[(Piperidin-1-yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-11-9P 685828-12-0P 685828-13-1P, 4-[5-[[2-(Morpholin-4-yl)ethoxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-14-2P, 3-Oxo-3-[2-[(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-4-yl)carbonyl]hydrazino]propionic acid tert-butyl ester 685828-15-3P, [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-yl]acetic acid tert-butyl ester 685828-16-4P, (3S)-3-Methoxypyrrolidine hydrochloride 685828-17-5P 685828-18-6P 685828-19-7P 685828-20-0P 685828-21-1P 685828-22-2P 685828-23-3P 685828-24-4P 685828-25-5P, Ethyl-[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-ylmethyl]amine 685828-26-6P, [2-[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-

ylmethoxy]ethyl]carbamic acid tert-butyl ester 685828-27-7P, [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-ylmethyl]carbamic acid tert-butyl ester 685828-28-8P 685828-29-9P 685828-30-2P **685828-31-3P**, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]carbamic acid tert-butyl ester **685828-32-4P 685828-33-5P 685828-34-6P 685828-35-7P**, [2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethyl]carbamic acid tert-butyl ester **685828-36-8P 685828-37-9P**, 4-(4-Benzyl-5-[(piperazin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-38-0P 685828-39-1P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 685828-40-4P, 4-[5-[(Morpholin-4-yl)methyl]-[1,3,4]oxadiazol-2-yl]piperidine-1-carboxylic acid tert-butyl ester 685828-41-5P, 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester 685828-42-6P, 4-[[4-Benzyl-5-(piperidin-4-yl)-4H-[1,2,4]triazol-3-yl]methyl]morpholine 685828-43-7P 685828-44-8P, 4-[(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)methyl]morpholine 685828-45-9P, 4-[[5-[4-(Pyridin-2-yl)piperazin-1-ylmethyl]-[1,3,4]oxadiazol-2-yl]methyl]morpholine 685828-46-0P, 4-[[5-[4-(Pyrimidin-2-yl)piperazin-1-ylmethyl]-[1,3,4]oxadiazol-2-yl]methyl]morpholine 685828-47-1P, 1-[[5-[1-(Pyrimidin-2-yl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl]methyl]piperidin-3-ol 685828-48-2P, (R)-2-[N'-[(3,4,5,6-Tetrahydro-2H-[1,2']bipyridin-4-yl)carbonyl]hydrazinocarbonyl]pyrrolidine-1-carboxylic acid tert-butyl ester 685828-50-6P, (R)-2-[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 685828-51-7P, (R)-4-[5-[[(Tetrahydrofuran-3-yl)oxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-52-8P, (S)-4-[5-[[(Tetrahydrofuran-3-yl)oxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-53-9P, [Methyl[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-ylmethyl]amino]acetic acid tert-butyl ester 685828-54-0P, N'-[(3,4,5,6-Tetrahydro-2H-[1,2']bipyridin-4-yl)carbonyl]tetrahydrofuran-2-carboxylic hydrazide 685828-55-1P, 4-[5-(Tetrahydrofuran-2-yl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-56-2P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid N'-(2-tetrahydropyran-4-ylacetyl)hydrazide 685828-57-3P, 4-[5-(Tetrahydropyran-4-ylmethyl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-58-4P, 4-(5-Ethoxymethyl-[1,3,4]oxadiazol-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-59-5P, 4-[5-(2-Methoxyethoxymethyl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-60-8P, [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-ylmethoxy]acetic acid tert-butyl ester 685828-62-0P, 4-[5-[(Pyrazol-1-yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-63-1P 685828-64-2P, 4-[5-[([1,2,3]Triazol-1-yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-65-3P, 4-[5-(Pyridin-4-yloxymethyl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

IT 79-30-1, Isobutyryl chloride 98-91-9, Benzenecarbothioic acid 108-12-3, 3-Methylbutyryl chloride 108-86-1, Bromobenzene, reactions 109-02-4, 4-Methylmorpholine 109-09-1, 2-Chloropyridine 109-85-3 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 288-13-1, 1H-Pyrazole 288-35-7, 2H-[1,2,3]Triazole 541-16-2, tert-Butyl malonate 622-40-2, 2-(Morpholin-4-yl)ethanol 626-64-2, 4-Hydroxypyridine 770-17-2 870-46-2, Hydrazinecarboxylic acid tert-butyl ester 1722-12-9, 2-Chloropyrimidine 2627-86-3, ((S)-(-)-1-Phenylethyl)amine 3430-17-9, 2-Bromo-3-methylpyridine 3538-65-6, Butyric acid hydrazide 4595-60-2, 2-Bromopyrimidine 5332-73-0 5616-81-9 6602-54-6, 2-Chloro-3-cyanopyridine 6859-99-0,

Piperidin-3-ol 14508-49-7, 2-Chloropyrazine 16874-33-2, Tetrahydrofuran-2-carboxylic acid 19810-31-2 26690-80-2, tert-Butyl N-(2-hydroxyethyl)carbamate 38291-82-6, Pentanoic acid hydrazide 40499-83-0, 3-Hydroxypyrrolidine 50595-15-8 51957-36-9, 1-(2-Pyrimidyl)piperidine 56613-80-0, (R)-(-)-2-Amino-2-phenylethanol 57260-71-6 65753-47-1, 2-Chloro-3-trifluoromethylpyridine 68654-52-4, 1-(2-Pyridyl)piperidine 86087-23-2, (S)-Tetrahydrofuran-3-ol 86087-24-3, (R)-Tetrahydrofuran-3-ol 101469-92-5, (3S)-3-Hydroxypyrrolidine-1-carboxylic acid tert-butyl ester 109431-87-0, (3R)-3-Hydroxypyrrolidine-1-carboxylic acid tert-butyl ester 111247-60-0, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic acid ethyl ester 120099-60-7 120099-61-8 130645-48-6, 2-Bromo-4-methylpyrimidine 154348-19-3, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid ethyl ester 187834-88-4, 4-(Hydrazinocarbonyl)piperidine-1-carboxylic acid tert-butyl ester 280110-69-2, 4-(5-Methyl-[1,3,4]oxadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 303144-44-7, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic acid 547716-11-0 685827-85-4 685828-49-3 685828-61-9, 4-[5-[(Methylsulfanyl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

IT **685827-43-4P**, 4-[4-Benzyl-5-[4-(methanesulfonyl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(V1A receptor antagonist, V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

RN 685827-43-4 HCAPLUS

CN Piperazine, 1-(methylsulfonyl)-4-[[4-(phenylmethyl)-5-[1-(2-pyridinyl)-4-piperidinyl]-4H-1,2,4-triazol-3-yl]methyl]- (9CI) (CA INDEX NAME)



1685194

=> d all hitstr l16 tot

L16 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:76225 HCAPLUS
DN 142:148824
ED Entered STN: 28 Jan 2005
TI Triazolyl compound vasopressin V1a receptor antagonists for the treatment of male sexual dysfunction, and screening assays
IN Wayman, Christopher Peter; Russell, Rachel Jane
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A41K031-41
ICS A61P015-12
CC 1-12 (Pharmacology)
Section cross-reference(s): 2
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

PI WO 2005006899 A1 20050127 WO 2004-IB2300 20040712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI WO 2003-IB17227 A 20030723
CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|
| WO 2005006899 | ICM | A41K031-41 |
| | ICS | A61P015-12 |
| WO 2005006899 | ECLA | A61K031/41; A61K031/4196 |

OS MARPAT 142:148824
AB The invention discloses the use of antagonists of vasopressin V1a receptors for the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The invention also discloses a method for treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The invention invention further discloses assays to screen for compds. useful in the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation, by screening for compds. which are V1a receptor antagonists. Compds. of the invention include e.g. 4-[4-benzyl-5-(4-methoxypiperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl.
ST Vasopressin V1a receptor antagonist male sexual dysfunction treatment; premature rapid ejaculation treatment Vasopressin V1a receptor antagonist; screening Vasopressin V1a receptor antagonist male sexual dysfunction treatment; triazolyl compd Vasopressin V1a antagonist male sexual dysfunction treatment
IT Vasopressin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(V1a; triazolyl compound vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
IT 5-HT reuptake inhibitors
(combination; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
IT Sexual behavior
(disorder; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
IT Sexual behavior
(ejaculation, rapid; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
IT Drug delivery systems
(injections, i.v.; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
IT Sexual behavior
(premature ejaculation; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
IT Radiochemical analysis
(receptor-binding; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
IT Drug delivery systems
(tablets; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
IT Combination chemotherapy
Drug delivery systems
Drug screening
Human

Second messenger system
(vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
IT 9068-52-4, Phosphodiesterase V
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, combination; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
IT 288-88-0D, 1H-1,2,4-Triazole, derivs. 162042-44-6, L 371257
685827-24-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Pfizer Ltd; WO 2004037809 A 2004 HCAPLUS
(2) Tobe, T; WO 0158880 A 2001 HCAPLUS
IT 685827-24-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)
RN 685827-24-1 HCAPLUS
CN Pyridine, 2-[4-[5-[(4-methoxy-1-piperidinyl)methyl]-4-(phenylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




L16 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:851132 HCAPLUS
DN 136:5994
ED Entered STN: 23 Nov 2001
TI Preparation of triazole derivatives as glycine transporter inhibitors useful as learning improving agents
IN Tobe, Takahiko; Sugane, Takashi; Hamaguchi, Wataru; Shimada, Itsuro; Maeno, Kyoichi; Miyata, Junji; Kimizuka, Tetsuya; Suzuki, Takeshi; Kohara, Atsuyuki; Morita, Takuma; Arlt, Michael; Greiner, Hartmut
PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Merck Patent Gesellschaft mit Beschrankter Haftung
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM C07D249-08
ICS C07D249-12; C07D401-04; C07D413-14; C07D405-14; C07D405-12; C07D405-04; C07D403-04; C07D413-04; C07D409-10; C07D417-10; C07D401-10; C07D401-14; C07D405-10; C07D401-16; C07D401-12; C07D495-04; A61K031-41; A61K031-4439; A61K031-4155
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2001087855 | A1 | 20011122 | WO 2001-JP4128 | 20010517 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| AU | 2001056769 | A5 | 20011126 | AU 2001-56769 | 20010517 |
| CA | 2409819 | AA | 20021118 | CA 2001-2409819 | 20010517 |
| EP | 1293503 | A1 | 20030319 | EP 2001-930192 | 20010517 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR | 2001010961 | A | 20040629 | BR 2001-10961 | 20010517 |
| NO | 2002005517 | A | 20021118 | NO 2002-5517 | 20021118 |
| US | 2003216385 | A1 | 20031120 | US 2002-276720 | 20021118 |
| ZA | 2002010245 | A | 20040318 | ZA 2002-10245 | 20021218 |
| US | 2004214818 | A1 | 20041028 | US 2004-848386 | 20040519 |
| PRAI JP | 2000-148419 | A | 20000519 | | |
| JP | 2001-47921 | A | 20010223 | | |
| WO | 2001-JP4128 | W | 20010517 | | |
| US | 2002-276720 | A3 | 20021118 ✓ | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|
| WO 2001087855 | ICM | C07D249-08 |
| | ICS | C07D249-12; C07D401-04; C07D413-14; C07D405-14; C07D405-12; C07D405-04; C07D403-04; C07D413-04; C07D409-10; C07D417-10; C07D401-10; C07D401-14; C07D405-10; C07D401-16; C07D401-12; C07D495-04; A61K031-41; A61K031-4439; A61K031-4155 |
| WO 2001087855 | ECLA | A61K031/41; A61K031/4155; A61K031/416; A61K031/427; A61K031/4439; A61K031/4709; A61K031/4725; A61K031/517; A61K031/5377; C07D249/08C3; C07D249/10; C07D249/12; C07D249/14; C07D401/04+249B+217; C07D401/04+249B+215; C07D401/04+249B+211; C07D401/06+249B+215; C07D401/06+249B+217; C07D401/10+249B+215; C07D401/14+249B+215+213; C07D403/04+249B+231; C07D403/04+249B+207; C07D403/04+249B+209C; C07D403/04+249B+235C; C07D403/10+249B+233; C07D403/10+257+249B; C07D405/04+307B+249B; C07D405/06+309+249B; C07D405/10+307+249B; C07D405/12+307B+249B; C07D405/12+309+249B; C07D405/14+307B+249B+213; C07D405/14+309+249B+213; C07D405/14+307B+249B+215+213; C07D409/10+333B+249B; C07D413/04+271+249B; C07D413/14+271+249B+2157; C07D417/04+285B+249B; C07D417/10+277B+249B; C07D495/04+333B+221B |
| EP 1293503 | ECLA | C07D249/10; C07D405/10+307+249B; C07D405/12+307B+249B; C07D405/12+309+249B; C07D405/14+307B+249B+213; C07D405/14+309+249B+213; C07D405/14+307B+249B+215+213; C07D409/10+333B+249B; C07D413/04+271+249B; C07D413/14+271+249B+2157; C07D417/04+285B+249B; C07D417/10+277B+249B; C07D495/04+333B+221B; C07D249/12; C07D249/14; C07D401/04+249B+217; C07D401/04+249B+215; C07D401/04+249B+211; C07D401/06+249B+215; C07D401/06+249B+217; C07D401/10+249B+215; C07D401/12+309+213; C07D401/14+249B+215+213; C07D403/04+249B+231; C07D403/04+249B+207; C07D403/04+249B+209C; C07D403/04+249B+235C; C07D403/10+249B+233; C07D403/10+257+249B; C07D405/04+307B+249B; C07D405/06+309+249B; C07D249/08C3 |
| US 2003216385 | NCL | 514/227.800 |
| | ECLA | A61K031/41; C07D403/04+249B+207; C07D403/04+249B+231; C07D403/10+249B+233; C07D403/10+257+249B; C07D405/04+307B+249B; C07D405/06+309+249B; C07D405/10+307+249B; C07D405/12+309+249B; C07D405/12+307B+249B; C07D405/14+307B+249B+215+213; |

C07D405/14+309+249B+213; C07D405/14+307B+249B+213;
C07D409/10+333B+249B; C07D413/04+271+249B;
C07D413/14+271+249B+2157; C07D417/04+285B+249B;
C07D417/10+277B+249B; C07D495/04+333B+221B;
A61K031/4155; A61K031/416; A61K031/427; A61K031/4439;
A61K031/4709; A61K031/4725; A61K031/517; A61K031/5377;
C07D249/08C3; C07D249/10; C07D249/12; C07D249/14;
C07D401/04+249B+211; C07D401/04+249B+215;
C07D401/04+249B+217; C07D401/06+249B+217;
C07D401/06+249B+215; C07D401/10+249B+215;
C07D401/12+309+213; C07D401/14+249B+215+213;
C07D403/04+249B+235C; C07D403/04+249B+209C

US 2004214818 NCL 514/217.090

ECLA A61K031/41; A61K031/4155; A61K031/416; A61K031/427;
A61K031/4439; A61K031/4709; A61K031/4725; A61K031/517;
A61K031/5377; C07D249/08C3; C07D249/10; C07D249/12;
C07D249/14; C07D401/04+249B+211; C07D401/04+249B+215;
C07D401/04+249B+217; C07D401/06+249B+215;
C07D401/06+249B+217; C07D401/10+249B+215;
C07D401/12+309+213; C07D401/14+249B+215+213;
C07D403/04+249B+207; C07D403/04+249B+209C;
C07D403/04+249B+231; C07D403/04+249B+235C;
C07D403/10+249B+233; C07D403/10+257+249B;
C07D405/04+307B+249B; C07D405/06+309+249B;
C07D405/10+307+249B; C07D405/12+307B+249B;
C07D405/12+309+249B; C07D405/14+307B+249B+213;
C07D405/14+307B+249B+215+213; C07D405/14+309+249B+213;
C07D409/10+333B+249B; C07D413/04+271+249B;
C07D413/14+271+249B+2157; C07D417/04+285B+249B;
C07D417/10+277B+249B; C07D495/04+333B+221B

OS MARPAT 136:5994

GI




I




II

AB Title compds. [I; A = aryl, heterocycly, cycloalkyl; B = aryl, pyridyl; D = aryl; R = H, CH3, CH3CH2, (CH3)2CH, CH3(CH2)2, CH3O(CH2)3, CH3CH2NH, (CH3)2N, CH3OCH2CH2NH], having glycine transporter inhibitory activity, are prepared for remedies as learning improving agents. Thus, the title compound II was prepared and biol. tested.

ST triazole prepn glycine transporter inhibitor learning improvement agent

IT Learning
(preparation of triazole derivs. as glycine transporter inhibitors useful as learning improving agents)

IT 374886-50-7P 374886-51-8P 374886-54-1P 374886-55-2P 374886-57-4P
374886-58-5P 374886-59-6P 374887-58-8P 374888-00-3P 374888-44-5P
374888-78-5P 374888-97-8P 374889-20-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole derivs. as glycine transporter inhibitors)

IT 348-54-9, 2-Fluoroaniline 611-34-7, 5-Quinolinamine 615-36-1, 2-Bromoaniline 626-55-1, 3-Bromopyridine 5933-32-4 6165-68-0, 2-Thienylboric acid 18622-23-6 29006-02-8 29051-44-3, 6-Phenylnicotinic acid 30379-55-6, Benzyloxyacetic acid 38256-93-8 38985-64-7, 2-Fluorophenylisothiocyanate 51362-48-2 135063-40-0 290366-59-5 374889-84-6 374889-87-9 374889-91-5 374889-98-2 374890-01-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazole derivs. as glycine transporter inhibitors)

IT 197079-04-2P 349129-99-3P 374889-30-2P 374889-31-3P 374889-32-4P
374889-33-5P 374889-34-6P 374889-35-7P 374889-36-8P 374889-37-9P
374889-38-0P 374889-39-1P 374889-40-4P 374889-41-5P 374889-42-6P
374889-43-7P 374889-44-8P 374889-45-9P 374889-46-0P 374889-47-1P
374889-48-2P 374889-49-3P 374889-50-6P 374889-51-7P 374889-52-8P
374889-53-9P 374889-54-0P 374889-55-1P 374889-56-2P 374889-57-3P
374889-58-4P 374889-59-5P 374889-60-8P 374889-61-9P 374889-62-0P
374889-63-1P 374889-64-2P 374889-65-3P 374889-66-4P 374889-67-5P
374889-68-6P 374889-69-7P 374889-70-0P 374889-71-1P 374889-72-2P
374889-73-3P 374889-74-4P 374889-75-5P 374889-76-6P 374889-77-7P
374889-78-8P 374889-79-9P 374889-80-2P 374889-81-3P 374889-82-4P
374889-83-5P 374889-85-7P 374889-86-8P 374889-88-0P 374889-89-1P
374889-90-4P 374889-92-6P 374889-93-7P 374889-94-8P 374889-95-9P
374889-96-0P 374889-97-1P 374889-99-3P 374890-00-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of triazole derivs. as glycine transporter inhibitors)

IT 374886-53-0P 374886-56-3P 374886-62-1P 374886-63-2P 374886-64-3P
374888-08-1P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazole derivs. as glycine transporter inhibitors)

IT 374886-52-9P 374886-60-9P 374886-61-0P 374886-65-4P 374886-66-5P
374886-67-6P 374886-68-7P 374886-69-8P 374886-70-1P 374886-71-2P
374886-72-3P 374886-73-4P 374886-74-5P 374886-75-6P 374886-76-7P
374886-77-8P 374886-78-9P 374886-79-0P 374886-80-3P 374886-81-4P
374886-82-5P 374886-83-6P 374886-84-7P 374886-85-8P 374886-86-9P
374886-87-0P 374886-88-1P 374886-89-2P 374886-90-5P 374886-91-6P
374886-92-7P 374886-93-8P 374886-94-9P 374886-95-0P 374886-96-1P
374886-97-2P 374886-98-3P 374886-99-4P 374887-00-0P 374887-01-1P
374887-02-2P 374887-03-3P 374887-04-4P 374887-05-5P 374887-06-6P
374887-07-7P 374887-08-8P 374887-09-9P 374887-10-2P 374887-11-3P
374887-12-4P 374887-13-5P **374887-14-6P** 374887-15-7P
**374887-16-8P** **374887-17-9P** 374887-18-0P 374887-19-1P
374887-20-4P 374887-21-5P 374887-22-6P 374887-23-7P 374887-24-8P
374887-25-9P 374887-26-0P 374887-27-1P 374887-28-2P 374887-29-3P
374887-30-6P 374887-31-7P 374887-32-8P 374887-33-9P 374887-34-0P
374887-35-1P 374887-36-2P 374887-37-3P 374887-38-4P 374887-39-5P
374887-40-8P 374887-41-9P 374887-42-0P 374887-43-1P 374887-44-2P
374887-45-3P 374887-46-4P 374887-47-5P 374887-48-6P 374887-49-7P
374887-50-0P 374887-51-1P 374887-52-2P 374887-53-3P 374887-54-4P
374887-55-5P 374887-56-6P 374887-57-7P 374887-59-9P 374887-60-2P
374887-61-3P 374887-62-4P 374887-63-5P 374887-64-6P 374887-65-7P
374887-66-8P 374887-67-9P 374887-68-0P 374887-69-1P 374887-70-4P
374887-71-5P 374887-72-6P 374887-73-7P 374887-74-8P 374887-75-9P
374887-76-0P 374887-77-1P 374887-78-2P 374887-79-3P 374887-80-6P
374887-81-7P 374887-82-8P 374887-83-9P 374887-84-0P 374887-85-1P
374887-86-2P 374887-87-3P 374887-88-4P 374887-89-5P 374887-90-8P
374887-91-9P 374887-92-0P 374887-93-1P 374887-94-2P 374887-95-3P

374887-96-4P 374887-97-5P 374887-98-6P 374887-99-7P 374888-01-4P
374888-02-5P 374888-03-6P 374888-04-7P 374888-05-8P 374888-06-9P
374888-07-0P 374888-09-2P 374888-10-5P 374888-11-6P 374888-12-7P
374888-13-8P 374888-14-9P 374888-15-0P 374888-16-1P 374888-17-2P
374888-18-3P 374888-19-4P 374888-20-7P 374888-21-8P 374888-22-9P
374888-23-0P 374888-24-1P 374888-25-2P 374888-26-3P 374888-27-4P
374888-28-5P 374888-29-6P 374888-30-9P 374888-31-0P 374888-32-1P
374888-33-2P 374888-34-3P 374888-35-4P 374888-36-5P 374888-37-6P
374888-38-7P 374888-39-8P 374888-40-1P 374888-41-2P 374888-42-3P
374888-43-4P 374888-45-6P 374888-46-7P 374888-47-8P 374888-48-9P
374888-49-0P 374888-50-3P 374888-51-4P 374888-52-5P 374888-53-6P
374888-54-7P 374888-55-8P 374888-56-9P 374888-57-0P 374888-58-1P
374888-59-2P 374888-60-5P 374888-61-6P 374888-62-7P 374888-63-8P
374888-64-9P 374888-65-0P 374888-66-1P 374888-67-2P 374888-68-3P
374888-69-4P 374888-70-7P 374888-71-8P 374888-72-9P 374888-73-0P
374888-74-1P 374888-75-2P 374888-76-3P 374888-77-4P 374888-79-6P
374888-80-9P 374888-81-0P 374888-82-1P 374888-83-2P 374888-84-3P
374888-85-4P 374888-86-5P 374888-87-6P 374888-88-7P 374888-89-8P
374888-90-1P 374888-91-2P 374888-92-3P 374888-93-4P 374888-94-5P
374888-95-6P 374888-96-7P 374888-98-9P 374888-99-0P 374889-00-6P
374889-01-7P 374889-02-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole derivs. as glycine transporter inhibitors)

IT 374889-03-9P 374889-04-0P 374889-05-1P 374889-06-2P 374889-07-3P
374889-08-4P 374889-09-5P 374889-10-8P 374889-11-9P 374889-12-0P
374889-13-1P 374889-14-2P 374889-15-3P 374889-16-4P 374889-17-5P
374889-18-6P 374889-19-7P 374889-21-1P 374889-22-2P 374889-23-3P
374889-24-4P 374889-25-5P 374889-26-6P 374889-27-7P 374889-28-8P
374889-29-9P 374890-03-6P 374890-04-7P 374890-05-8P 374890-06-9P
374890-07-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole derivs. as glycine transporter inhibitors)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Boehringer Ingelheim Kg; JP 01275571 A HCAPLUS
(2) Boehringer Ingelheim Kg; DE 3808283 A HCAPLUS
(3) Boehringer Ingelheim Kg; EP 335144 A 1989 HCAPLUS
(4) Dr Kahl Thomae Gmbh; DE 4302051 A HCAPLUS
(5) Dr Kahl Thomae Gmbh; JP 72851 A
(6) Dr Kahl Thomae Gmbh; EP 608858 A 1994 HCAPLUS
(7) Pfizer Research And Development Company N VS A; JP 11506123 A
(8) Pfizer Research And Development Company N VS A; EP 885212 A HCAPLUS
(9) Pfizer Research And Development Company N VS A; WO 9732873 A 1997 HCAPLUS
(10) Yamanouchi Pharmaceutical Co Ltd; JP 200063363 A 2000

IT **374887-14-6P 374887-16-8P 374887-17-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole derivs. as glycine transporter inhibitors)

RN 374887-14-6 HCAPLUS

CN Piperidine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 374887-16-8 HCAPLUS
CN Piperidine, 4-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-1-phenyl-
(9CI) (CA INDEX NAME)





RN 374887-17-9 HCAPLUS
CN Piperazine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl-
(9CI) (CA INDEX NAME)



=> b uspatall
FILE 'USPATFULL' ENTERED AT 09:24:59 ON 22 SEP 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:24:59 ON 22 SEP 2005

=> d bib abs fhitstr hitrn l17 tot

L17 ANSWER 1 OF 3 USPATFULL on STN
AN 2005:31373 USPATFULL
TI Treatment of male sexual dysfunction
IN Wayman, Christopher Peter, Sandwich, UNITED KINGDOM
Russell, Rachel Jane, Sandwich, UNITED KINGDOM
PA Pfizer Inc. (non-U.S. corporation)
PI US 2005026810 A1 20050203
AI US ~~2004-895630~~ A1 20040720 (10)
PRAI GB 2003-17227 20030723
US 2003-493823P 20030808 (60)
DT Utility
FS APPLICATION
LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10 895 63?

AB The present invention relates the use of antagonists of vasopressin V1a receptors for the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The present invention also relates to a method of treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The present invention also relates to assays to screen for compounds useful in the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation, by screening for compounds which are V1a receptor antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine
(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
RN 748806-15-7 USPATFULL
CN 4H-1,2,4-Triazole-3-methanamine, N-[1-(2-amino-5-chlorophenyl)ethyl]-4-(4-chlorophenyl)-N-methyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




IT 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine
(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

Search done by Noble Jarrell

FILE COVERS 1907 - 22 Sep 2005 VOL 143 ISS 13
FILE LAST UPDATED: 21 Sep 2005 (20050921/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all fhitstr l15 tot

L15 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:718543 HCAPLUS
DN 141:225517
ED Entered STN: 02 Sep 2004
TI Preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea
IN Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas; Stobie, Alan
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D487-04
ICS A61K031-55; A61K031-501; A61K031-4427; A61P029-00; C07D498-04; C07D401-04; C07D413-14; C07D513-04; C07D249-00; C07D243-00; C07D267-00
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2004074291 | A1 | 20040902 | WO 2004-IB432 | 20040209 |
| | W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2004186091 | A1 | 20040923 | US 2004-782285 | 20040218 |
| | NL 1025527 | A1 | 20040823 | NL 2004-1025527 | 20040219 |
| | NL 1025527 | C2 | 20050314 | | |
| | US 2005026810 | A1 | 20050203 | US 2004-895630 | 20040720 |
| PRAI | GB 2003-3852 | A | 20030219 | | |
| | GB 2003-17227 | A | 20030723 | | |
| | US 2003-455455P | P | 20030318 | | |
| | US 2003-493823P | P | 20030808 | | |

#10782285

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|
| WO 2004074291 | ICM | C07D487-04 |
| | ICS | A61K031-55; A61K031-501; A61K031-4427; A61P029-00; |

L17 ANSWER 2 OF 3 USPATFULL on STN
AN 2004:240276 USPATFULL
TI Triazole compounds useful in therapy
IN Bryans, Justin Stephen, Sandwich, UNITED KINGDOM
Johnson, Patrick Stephen, Sandwich, UNITED KINGDOM
Ryckmans, Thomas, Sandwich, UNITED KINGDOM
Stobie, Alan, Sandwich, UNITED KINGDOM
PA Pfizer Inc (non-U.S. corporation)
PI US 2004186091 A1 20040923
AI US 2004-782285 A1 20040218 (10)
PRAI GB 2003-3852 20030219
US 2003-455455P 20030318 (60)
DT Utility
FS APPLICATION
LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4730
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula (I), ##STR1##

or a pharmaceutically acceptable derivative thereof, wherein

V represents --(CH.sub.2).sub.d(O).sub.e--, --CO--, or --CH(C.sub.1-6 alkyl)-;

W is --O--, --S(O).sub.a--, or --N(R.sup.1)--

R.sup.1 represents H, C.sub.1-6 alkyl, (CH.sub.2).sub.bCOR.sup.2, CO(CH.sub.2).sub.bNR.sup.2R.sup.3, SO.sub.2R.sup.2, (CH.sub.2).sub.cOR.sup.2, (CH.sub.2).sub.cNR.sup.2R.sup.3, or (CH.sub.2).sub.bhet.sup.1;

het.sup.1 represents a saturated or unsaturated heterocycle of from 3 to 8 atoms containing one or more heteroatoms selected from O, N, or S, optionally substituted with C.sub.1-6 alkyl;

X and Y independently represent H, C.sub.1-6 alkyl, halogen, OH, CF.sub.3, OCF.sub.3, OR.sup.4;

Z represents --(CH.sub.2).sub.f(O).sub.g--, --CO-- or --CH(C.sub.1-6 alkyl)-;

Ring A represents a 4-7 membered, saturated N-containing heterocycle, optionally substituted with OH, and in which optionally at least one ring N is substituted with O;

Ring B represents phenyl or a 4-7 membered unsaturated N-containing heterocycle, optionally substituted with OH, halogen, CN, CONH.sub.2, CF.sub.3, OCF.sub.3, and in which optionally at least one ring N is substituted with O;

R.sup.2 and R.sup.3 independently represent H, C.sub.1-6 alkyl [optionally substituted with OH, halogen, N(C.sub.1-6 alkyl).sub.2, or C.sub.1-6 alkyloxy], C.sub.1-6 alkyloxy, N(C.sub.1-6 alkyl).sub.2, or [C.sub.3-8 cycloalkyl];

or R.sup.2 and R.sup.3, together with the nitrogen atom to which they are attached independently represent a heterocycle of from 3 to 8 atoms, optionally substituted with C.sub.1-6 alkyl;

R.sup.4 represents straight or branched C.sub.1-6 alkyl,

a and c independently represent 0, 1, or 2;

b, e and g independently represent 0 or 1;

d and f independently represent 1 or 2;

are useful in the treatment of dysmenorrhoea

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **748806-15-7P**, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine
(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
RN 748806-15-7 USPATFULL
CN 4H-1,2,4-Triazole-3-methanamine, N-[1-(2-amino-5-chlorophenyl)ethyl]-4-(4-chlorophenyl)-N-methyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




IT **748806-15-7P**, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine
(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

L17 ANSWER 3 OF 3 USPATFULL on STN
AN **2004:209844** USPATFULL
TI Triazole compounds useful in therapy
IN Armour, Robert Duncan, Sandwich, UNITED KINGDOM
Baxter, Andrew Douglas, Sandwich, UNITED KINGDOM
Bryans, Justin Stephen, Sandwich, UNITED KINGDOM
Dack, Kevin Neil, Sandwich, UNITED KINGDOM
Johnson, Patrick Stephen, Sandwich, UNITED KINGDOM
Lewthwaite, Russell Andrew, Sandwich, UNITED KINGDOM
Newman, Julie, Sandwich, UNITED KINGDOM
Rawson, David James, Sandwich, UNITED KINGDOM
Ryckmans, Thomas, Sandwich, UNITED KINGDOM
PA Pfizer Inc (non-U.S. corporation)
PI US 2004162278 A1 20040819
AI US 2003-693327 A1 20031024 (10)
PRAI GB 2002-24919 20021025
US 2002-428632P 20021122 (60)
DT Utility
FS APPLICATION
LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of formula (I), ##STR1##

the pharmaceutically acceptable salts and solvates thereof, wherein A, B, R.sup.1, R.sup.2, and R.sup.7 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof as vasopressin V.sub.1A antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **685827-43-4P**, 4-[4-Benzyl-5-[4-(methanesulfonyl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
(V1A receptor antagonist, V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

RN 685827-43-4 USPATFULL

CN Piperazine, 1-(methylsulfonyl)-4-[[4-(phenylmethyl)-5-[1-(2-pyridinyl)-4-piperidinyl]-4H-1,2,4-triazol-3-yl]methyl]- (9CI) (CA INDEX NAME)



IT **685827-43-4P**, 4-[4-Benzyl-5-[4-(methanesulfonyl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
(V1A receptor antagonist, V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT **685827-36-5P**, 4-[4-(3-Chlorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-69-4P**, 4-[4-Benzyl-5-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
(V1A receptor antagonist; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

IT **685827-26-3P**, Benzyl 4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazine-1-carboxylate
(V1a receptor antagonist, intermediate; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT **685826-99-7P**, (S)-4-[5-Butyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-00-3P**, 2-[4-(4-Benzyl-5-isobutyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-01-4P**, (S)-4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-02-5P**, 4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-03-6P**, 2-[4-(4-Benzyl-5-isopropyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-05-8P**, (S)-2-[4-[5-Methyl-4-(1-phenylpropyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-06-9P**, 2-[4-(4-Benzyl-5-propyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-07-0P**, 2-[4-[4-Benzyl-5-(2-chlorophenoxymethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-08-1P**, 2-[4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-09-2P**, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-10-5P**, 2-[4-[4-Benzyl-5-(4-fluorophenoxymethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-11-6P**, 2-[4-[5-Methyl-4-(3-methylbenzyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-12-7P**, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-ylmethyl]piperidin-1-yl]pyrimidine **685827-13-8P**, 2-[4-[4-(3-Fluorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine **685827-14-9P**, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-15-0P**, 4-[4-Benzyl-5-[(benzyloxy)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-

tetrahydro-2H-[1,2']bipyridinyl **685827-16-1P**,
4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-17-2P**, (R)-2-[3-Methyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-[1,2,4]triazol-4-yl]-2-phenylethanol **685827-19-4P**, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine **685827-20-7P**, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-1-phenylpiperidine **685827-21-8P**, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrazine **685827-22-9P**, 4-(4-Benzyl-5-[(piperidin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-23-0P**, (S)-4-[4-(1-Phenylethyl)-5-[(piperidin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-24-1P**, 4-[4-Benzyl-5-(4-methoxypiperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-25-2P**, (S)-4-[5-(4-Methoxypiperidin-1-ylmethyl)-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-27-4P**, 4-[4-Benzyl-5-[[2-(morpholin-4-yl)ethoxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-28-5P**, 4-[4-Benzyl-5-((3R)-3-methoxypyrrolidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-29-6P** **685827-30-9P** **685827-31-0P** **685827-32-1P** **685827-33-2P** **685827-34-3P** **685827-35-4P** **685827-37-6P**, N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]acetamide **685827-38-7P**, 2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethylamine **685827-39-8P**, N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]ethylamine **685827-40-1P**, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)amine **685827-41-2P**, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)amine **685827-42-3P**, 1-[4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazin-1-yl]ethanone **685827-44-5P**, N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]methanesulfonamide **685827-45-6P**, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)methylamine **685827-46-7P**, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)methylamine **685827-51-4P**, (S)-4-[[4-(1-Phenylethyl)-5-[4-(pyridin-2-yl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]methyl]morpholine trihydrochloride **685827-52-5P**, (S)-4-[[4-(1-Phenylethyl)-5-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]-4H-[1,2,4]triazol-3-yl]methyl]morpholine trihydrochloride **685827-53-6P**, 1-[[4-Benzyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]piperidin-3-ol **685827-55-8P**, (R)-4-[4-Benzyl-5-[[(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-56-9P**, (S)-4-[4-Benzyl-5-[[(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-57-0P**, [[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]methylamino]acetic acid tert-butyl ester **685827-58-1P**, 4-[4-Benzyl-5-(tetrahydropyran-4-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-60-5P**, 4-[4-Benzyl-5-(ethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-61-6P**, 4-[4-Benzyl-5-(2-methoxyethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl **685827-62-7P**, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]acetic acid tert-butyl ester **685827-63-8P**, N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]acetamide **685827-64-9P**, 4-[4-Benzyl-5-[(methylsulfanyl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

685827-65-0P, 4-(4-Benzyl-5-[(pyrazol-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
685827-66-1P, 4-(4-Benzyl-5-[([1,2,3]triazol-2-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
685827-68-3P, 4-[4-Benzyl-5-(pyridin-4-yloxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
(V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 685828-31-3P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]carbamic acid tert-butyl ester
685828-32-4P 685828-33-5P 685828-34-6P
685828-35-7P, [2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethyl]carbamic acid tert-butyl ester 685828-36-8P 685828-37-9P,
4-(4-Benzyl-5-[(piperazin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
(intermediate; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

=> d bib abs hitstr l18 tot

L18 ANSWER 1 OF 2 USPATFULL on STN
AN 2004:274316 USPATFULL
TI Triazole derivative
IN Tobe, Takahiko, Tsukuba-shi, JAPAN
Sugane, Takashi, Tsukuba-shi, JAPAN
Hamaguchi, Wataru, Tsukuba-shi, JAPAN
Shimada, Itsuro, Tsukuba-shi, JAPAN
Maeno, Kyoichi, Tsukuba-shi, JAPAN
Miyata, Junji, Tsukuba-shi, JAPAN
Kimizuka, Tetsuya, Itabashi-ku, JAPAN
Suzuki, Takeshi, Tsukuba-shi, JAPAN
Kohara, Atsuyuki, Tsukuba-shi, JAPAN
Morita, Takuma, Tsukuba-shi, JAPAN
Arlt, Michael, Seeheim Jugenheim, GERMANY, FEDERAL REPUBLIC OF
Greiner, Hartmut, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
PA YAMANOUCHI PHARMACEUTICAL CO., LTD., MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (non-U.S. corporation)
PI US 2004214818 A1 20041028
AI US 2004-848386 A1 20040519 (10)
RLI Division of Ser. No. US 2002-276720, filed on 18 Nov 2002, PENDING A 371 of International Ser. No. WO 2001-JP4128, filed on 17 May 2001, UNKNOWN
PRAI JP 2000-148419 20000519
JP 2001-47921 20010223
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **374887-14-6P 374887-16-8P 374887-17-9P**
(preparation of triazole derivs. as glycine transporter inhibitors)
RN 374887-14-6 USPATFULL
CN Piperidine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 374887-16-8 USPATFULL
CN Piperidine, 4-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-1-phenyl- (9CI) (CA INDEX NAME)







RN 374887-17-9 USPATFULL
CN Piperazine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



L18 ANSWER 2 OF 2 USPATFULL on STN
AN 2003:306949 USPATFULL
TI Triazole derivatives
IN Tobe, Takahiko, Tsukuba-shi, JAPAN
Sugane, Takashi, Tsukuba-shi, JAPAN
Hamaguchi, Wataru, Tsukuba-shi, JAPAN
Shimada, Itsuro, Tsukuba-shi, JAPAN
Maeno, Kyoichi, Tsukuba-shi, JAPAN
Miyata, Junji, Tsukuba-shi, JAPAN
Kimizuka, Tetsuya, Itabashi-ku, JAPAN
Suzuki, Takeshi, Tsukuba-shi, JAPAN
Kohara, Atsuyuki, Tsukuba-shi, JAPAN
Morita, Takuma, Tsukuba-shi, JAPAN
Arlt, Michael, Jugenheim, GERMANY, FEDERAL REPUBLIC OF
Greiner, Hartmut, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
PI US 2003216385 A1 20031120
AI US 2002-276720 A1 20021118 (10)
WO 2001-JP4128 20010517
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., WASHINGTON, DC, 20037
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2523
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **374887-14-6P 374887-16-8P 374887-17-9P**
(preparation of triazole derivs. as glycine transporter inhibitors)
RN 374887-14-6 USPATFULL
CN Piperidine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 374887-16-8 USPATFULL
CN Piperidine, 4-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-1-phenyl- (9CI) (CA INDEX NAME)







RN 374887-17-9 USPATFULL
CN Piperazine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl-
(9CI) (CA INDEX NAME)




=> b home
FILE 'HOME' ENTERED AT 09:25:57 ON 22 SEP 2005

=>